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Optimization of Lead Spectinamide Compounds as Novel Anti-tuberculosis
Agents with a Pharmacometric Approach
Abstract
In an effort to combat the global Tuberculosis pandemic, Dr.Richard E. Lee and his group at St.Jude
Children’s Research Hospital designed a novel series of anti-tuberculosis agents, spectinamides – semisynthetic analogs of spectinomycin. Spectinamides are a potent inhibitor of mycobacterial ribosomes
and overcome efflux mediated drug resistance in M. tb. Spectinamides have shown an excellent in vitro
activity, which makes them well suited for further lead optimization and preclinical development. We
hypothesized that through pharmacokinetic (PK) and pharmacodynamics (PD) model-based dosing
optimization studies, we could strategically guide the selection and refinement of more potent and
effective anti-TB spectinamides. Biopharmaceutical in vitro screening demonstrated that spectinamides
in general have low plasma protein binding and are stable against hepatic microsomal metabolism. In
vivo pharmacokinetic studies in rats revealed that the kidneys are the major route of elimination for
spectinamides in their unchanged form. Radiolabeled biodistribution studies showed 84.7% of
radioactivity accumulated 70% in urine, 12.6% in feces, and the remainder in the blood and other major
organs. The unaccounted for residual 15.3% likely distributed into the epidermis and other surface tissue.
In multiple-dose accumulation studies, the Cmax of radiolabeled compound after the 1st dose and the 8th
dose of twice-daily dosing regimen was similar: 3.39µCi/mL and 3.55µCi/mL, suggesting no relevant
accumulation of parent drug and metabolites. The concentration of radiolabeled compound was three
times more in lungs and spleen as compared to whole blood, suggesting good tissue penetration.
Macrophage uptake studies showed that Lee 1329, Lee1445 and Lee 1599 had significantly higher
macrophage uptake than spectinomycin and streptomycin. Lee 1329 showed 6-fold and 2.2-fold higher
uptake than streptomycin and spectinomycin, respectively. Based on the results of the in vitro
experiments and preliminary PK/PD studies in rats, Lee 1599 was selected as the lead candidate
compound. To predict PK/PD indices of antimicrobial efficacy, we performed model-based dosing
optimization studies with Lee 1599. We used an in vitro PK/PD model system to simulate the rat PK
conditions while evaluating antibacterial activities to predict effective dosing regimens for further in vivo
efficacy studies. Our results have shown that Lee 1599 exhibits dose-dependent bactericidal effect. Lee
1599 showed up to 4-log reductions in bacterial counts at 100mg QD dosing. The PK/PD indices
demonstrated that Lee 1599 elicits a concentration- and time-dependent killing with AUC/MIC as the
optimal index. The model was put through numerical simulations to predict the effect of Lee 1599 in mice
at various dosing regimens. The in vitro PK/PD simulated profile has suggested that high doses with
frequent dosing intervals may demonstrate optimum in vivo efficacy. Consequently, we aimed to
determine the pharmacodynamic interaction between Lee 1599 and existing anti-tuberculosis agent. We
selected rifampicin as a model compound and applied a parametric approach to quantitatively assess the
pharmacodynamic drug interaction between Lee 1599 and rifampicin. The three dimensional surface
response assay demonstrated that there is an additive effect between both the agents as opposed to the
conventional checkerboard assay, which suggested synergism between these agents. The results of
surface response assay were validated using an in vitro PK/PD model for combination agents and in vivo
efficacy trials, which showed an additive effect between Lee 1599 and rifampicin. Thus, quantitative
assays such as the surface response assay seem to provide more reliable information on
pharmacodynamic interactions as opposed to qualitative methods such as checkerboard assay. In
conclusion, we have successfully supported the further development of spectinamides using a
pharmacometric approach. We have identified a lead candidate compound Lee 1599 using an iterative
PK/PD approach for its pre-clinical drug development. The application of PK/PD knowledge is essential
for translating the in vitro screening assay findings to the in vivo stage, thus accelerating the drug
development process. The results of the above studies can be used as a roadmap for the optimization of
anti-infective agents in the early drug discovery and pre-clinical developmental phase.
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ABSTRACT
In an effort to combat the global Tuberculosis pandemic, Dr.Richard E. Lee and
his group at St.Jude Children’s Research Hospital designed a novel series of antituberculosis agents, spectinamides – semi-synthetic analogs of spectinomycin.
Spectinamides are a potent inhibitor of mycobacterial ribosomes and overcomes efflux
mediated drug resistance in M. tb.
Spectinamides have shown an excellent in vitro activity, which makes them well
suited for further lead optimization and preclinical development. We hypothesized that
through pharmacokinetic (PK) and pharmacodynamics (PD) model-based dosing
optimization studies, we could strategically guide the selection and refinement of more
potent and effective anti-TB spectinamides.
Biopharmaceutical in vitro screening demonstrated that spectinamides in general
have low plasma protein binding and are stable against hepatic microsomal metabolism.
In vivo pharmacokinetic studies in rats revealed that the kidneys are the major route of
elimination for spectinamides in their unchanged form. Radiolabeled biodistribution
studies showed 84.7% of radioactivity accumulated 70% in urine, 12.6% in feces, and the
remainder in the blood and other major organs. The unaccounted for residual 15.3%
likely distributed into the epidermis and other surface tissue. In multiple-dose
accumulation studies, the Cmax of radiolabeled compound after the 1st dose and the 8th
dose of twice-daily dosing regimen was similar: 3.39μCi/mL and 3.55μCi/mL, suggesting
no relevant accumulation of parent drug and metabolites. The concentration of
radiolabeled compound was three times more in lungs and spleen as compared to whole
blood, suggesting good tissue penetration. Macrophage uptake studies showed that Lee
1329, Lee1445 and Lee 1599 had significantly higher macrophage uptake than
spectinomycin and streptomycin. Lee 1329 showed 6-fold and 2.2-fold higher uptake
than streptomycin and spectinomycin, respectively.
Based on the results of the in vitro experiments and preliminary PK/PD studies in
rats, Lee 1599 was selected as the lead candidate compound. To predict PK/PD indices of
anti-microbial efficacy, we performed model-based dosing optimization studies with Lee
1599. We used an in vitro PK/PD model system to simulate the rat PK conditions while
evaluating antibacterial activities to predict effective dosing regimens for further in vivo
efficacy studies. Our results have shown that Lee 1599 exhibits dose-dependent
bactericidal effect. Lee 1599 showed up to 4-log reductions in bacterial counts at 100mg
QD dosing. The PK/PD indices demonstrated that Lee 1599 elicits a concentration- and
time-dependent killing with AUC/MIC as the optimal index. The model was put through
numerical simulations to predict the effect of Lee 1599 in mice at various dosing
regimens. The in vitro PK/PD simulated profile has suggested that high doses with
frequent dosing intervals may demonstrate optimum in vivo efficacy.
Consequently, we aimed to determine the pharmacodynamic interaction between
Lee 1599 and existing anti-tuberculosis agent. We selected rifampicin as a model
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compound and applied a parametric approach to quantitatively assess the
pharmacodynamic drug interaction between Lee 1599 and rifampicin. The three
dimensional surface response assay demonstrated that there is an additive effect between
both the agents as opposed to the conventional checkerboard assay, which suggested
synergism between these agents. The results of surface response assay were validated
using an in vitro PK/PD model for combination agents and in vivo efficacy trials, which
showed an additive effect between Lee 1599 and rifampicin. Thus, quantitative assays
such as the surface response assay seem to provide more reliable information on
pharmacodynamic interactions as opposed to qualitative methods such as checkerboard
assay.
In conclusion, we have successfully supported the further development of
spectinamides using a pharmacometric approach. We have identified a lead candidate
compound Lee 1599 using an iterative PK/PD approach for its pre-clinical drug
development. The application of PK/PD knowledge is essential for translating the in vitro
screening assay findings to the in vivo stage, thus accelerating the drug development
process. The results of the above studies can be used as a roadmap for the optimization of
anti-infective agents in the early drug discovery and pre-clinical developmental phase.

vii

TABLE OF CONTENTS
CHAPTER 1. APPLICATION OF PHARMACOMETRICS IN THE
CLINICAL DRUG DEVELOPMENT OF ANTI-INFECTIVES .................................1
Introduction ......................................................................................................................1
Pharmacometrics in Anti-infective Drug Development ..................................................1
Prerequisites for the Application of Pharmacometrics ....................................................3
PK/PD Indices and Susceptibility Breakpoints ...............................................................9
Development of Optimal Dosing Regimens ..................................................................13
Optimization of Clinical Studies and Clinical Applications ..........................................15
Future Prospects .............................................................................................................16
CHAPTER 2. CENTRAL HYPOTHESIS ....................................................................19
Specific Aim 1 ...............................................................................................................19
Specific Aim 2 ...............................................................................................................19
Specific Aim 3 ...............................................................................................................20
CHAPTER 3. PHARMACOKINETICS AND BIODISTRIBUTION OF A
NOVEL SERIES OF ANTI-TUBERCULOSIS AGENTS: SPECTINAMIDES .......21
Introduction ....................................................................................................................21
Materials and Methods...................................................................................................21
Chemicals and reagents ..............................................................................................21
Protein binding ...........................................................................................................22
Formulation preparation and administration ..............................................................22
Pharmacokinetic studies .............................................................................................22
Pharmacokinetic data analysis ...................................................................................24
Macrophage uptake assay ..........................................................................................25
Sample preparation and LC-MS/MS analysis ............................................................25
Biodistribution ...........................................................................................................26
Sample preparation of biological samples for 3H-1329 .............................................26
Blood ..................................................................................................................... 26
Serum and urine .................................................................................................... 27
Organs and muscle tissue ...................................................................................... 27
Feces ..................................................................................................................... 27
Sample analysis of biological samples for 3H-1329 ..................................................27
Results and Discussion ..................................................................................................28
Biopharmaceutical properties of spectinamides ........................................................28
Macrophage uptake assay ..........................................................................................37
Biodistribution ...........................................................................................................37
Mass balance ......................................................................................................... 41
Tissue distribution ................................................................................................. 41
Pharmacokinetic profile of radioactivity in serum................................................ 41
Conclusion .....................................................................................................................48

viii

CHAPTER 4. A PHARMACOMETRICS-BASED APPROACH USING IN
VITRO PK/PD MODELING TO DEVELOP DOSING REGIMENS FOR IN
VIVO STUDIES FOR A NOVEL SPECTINAMIDE ANTI-TUBERCULOSIS
AGENT .............................................................................................................................49
Introduction ....................................................................................................................49
Materials and Methods...................................................................................................50
Culture, media and antibiotics ...................................................................................50
In vitro PK/PD model ................................................................................................50
Time kill curves for Lee 1599 ....................................................................................52
PK/PD model building ...............................................................................................52
Numerical simulations ...............................................................................................54
Results ............................................................................................................................55
Time kill curves for Lee 1599 ....................................................................................55
Numerical simulations ...............................................................................................63
Discussion ......................................................................................................................63
Conclusions ....................................................................................................................71
CHAPTER 5. APPLICATION OF PHARMACOMETRIC TOOLS FOR
IDENTIFYING PHARMACODYNAMIC INTERACTIONS IN ANTIBIOTIC
COMBINATIONS ...........................................................................................................72
Introduction ....................................................................................................................72
Materials and Methods...................................................................................................73
Antimicrobial agents ..................................................................................................73
Microorganisms .........................................................................................................73
Checkerboard assay ...................................................................................................73
Response surface assay ..............................................................................................74
In vitro PK/PD model ................................................................................................75
Time kill curves for Lee 1599 ....................................................................................77
In vivo efficacy studies ...............................................................................................77
Results ............................................................................................................................77
Checkerboard assay ...................................................................................................77
Response surface assay ..............................................................................................78
In vitro PK/PD model for combination agents...........................................................78
In vivo studies ............................................................................................................85
Discussion ......................................................................................................................85
Conclusions ....................................................................................................................93
CHAPTER 6. SUMMARY ..............................................................................................94
LIST OF REFERENCES ................................................................................................96
VITA................................................................................................................................104

ix

LIST OF TABLES
Table 1-1.

Examples of the application of pharmacometrics analyses for antiinfectives. .......................................................................................................4

Table 3-1.

Physico-chemical properties and pharmacokinetic parameters for
spectinamides after intravenous administration at 10mg/kg dose. ...............29

Table 3-2.

Mean concentration of drug uptake into J774A.1 murine macrophage
cell line at 24h for two different doses. ........................................................38

Table 3-3.

Tissue distribution and recovery of radioactivity (mean(%CV))
following IV administration of 3H-1329 at 0.9mg/kg BID for 4.5days in
rats. ...............................................................................................................44

Table 3-4.

Serum pharmacokinetic parameters after the 1st and 8th intravenous
dose of 0.9mg/kg 3H-1329 (values are expressed as mean (%CV)). ...........47

Table 4-1.

In vitro PK/PD parameter estimates for Lee 1599. .......................................58

Table 4-2.

Empirical PK/PD indices based on day 4 data..............................................62

Table 5-1.

Checkerboard assay results to determine pharmacodynamic interaction
between Lee 1599 and RIF. ..........................................................................79

Table 5-2.

Results of three dimensional surface response assay. ...................................83

Table 5-3.

Summary of results of pharmacodynamics interactions from different
methods. .......................................................................................................89

Table 5-4.

Comparison of %AUC ratios (the %AUC were normalized with AUC of
control group). ..............................................................................................91

x

LIST OF FIGURES
Figure 1-1. Illustration of interplay of pharmacology, microbiology, physiology,
disease and their association with pharmacometric evaluations in the
clinical development and application of anti-infectives. ................................2
Figure 1-2. Illustration of the PK/PD indices at steady state during multiple dosing:
(i) T>MIC: Time above MIC (ii) Cmax/MIC (iii) AUC/MIC. ....................10
Figure 3-1. Chemical structure of lead spectinamides with MIC values. ........................23
Figure 3-2. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee
1544 in rats. ..................................................................................................30
Figure 3-3. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee
1599 in rats. ..................................................................................................31
Figure 3-4. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee
1601 in rats. ..................................................................................................32
Figure 3-5. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee
1603 in rats. ..................................................................................................33
Figure 3-6. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee
1661 in rats. ..................................................................................................34
Figure 3-7. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) administration of Lee 1666 in rats. ........................35
Figure 3-8. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) administration of spectinomycin in rats. ................36
Figure 3-9. Mean average concentrations (± SEM) of drug uptake into J774A.1
murine macrophage cell line at 24h. ............................................................39
Figure 3-10. Fold differences in drug uptake in J774A.1 murine macrophage cell line. ..40
Figure 3-11. Mass balance and percentage distribution of Lee 1329-T at 1h post 9th
dose of 0.9mg/kg. .........................................................................................42
Figure 3-12. Amount of radioactivity (mean ± SD) excreted in urine after each dosing
interval (0.9mg/kg 3H-1329, BID for 4.5days). ...........................................43

xi

Figure 3-13. Fold difference (mean ± SD) in tissue distribution of radioactivity
compared to amount in whole blood (after normalizing the distributions
to μCi/mL or μCi/mg of blood or tissue). ....................................................45
Figure 3-14. Comparison of single and multiple dose pharmacokinetics showing
average (±SD) serum concentration-time profiles of radioactivity after
the 1st dose and 8th dose during multiple dosing with 0.9mg/kg 3H1329 given intravenously every 12h. ...........................................................46
Figure 4-1. A representation of working unit of an in vitro PK/PD model. ....................51
Figure 4-2. Schematic representation of PK/PD model to describe the rate of change
in the number of bacteria in the in vitro PK/PD model system. ...................53
Figure 4-3. Timekill effect of Lee 1599 against M. bovis BCG (N0: 6-7 log
CFU/mL) with observed log CFU/mL plotted against time for different
dosing regimens. ...........................................................................................56
Figure 4-4. Timekill effect of Lee 1599 against M. bovis BCG (N0: 7-8 log
CFU/mL) with observed log CFU/mL plotted against time for different
dosing regimens. ...........................................................................................57
Figure 4-5. Panels showing goodness of fit plots for the Lee 1599 PK/PD model fit
(A.) DV vs PRED (B.) DV vs IPRED (C.) PRED vs CWRES (D.)
TIME vs CWRES. ........................................................................................59
Figure 4-6. Plots showing measured (DV is observed data), individual predictions
IPRED (black lines) and population predictions (red lines) for M. bovis
BCG CFU/mL over time for the Lee 1599 PK/PD model. ..........................60
Figure 4-7. Relationship between PK/PD indices and microbial kill on Day 4 after
treatment. ......................................................................................................61
Figure 4-8. Schematic representation of PK/PD model used for simulations. ................64
Figure 4-9. Time kill curves calculated from 1000 numerical simulations for once
daily dosing regimen of Lee 1599 in mice. ..................................................65
Figure 4-10. Time kill curves calculated from 1000 numerical simulations for twice
daily dosing regimen of Lee 1599 in mice. ..................................................66
Figure 4-11. Time kill curves calculated from 1000 numerical simulations for thrice
daily dosing regimen of Lee 1599 in mice. ..................................................67
Figure 4-12. Time kill curves calculated from 1000 numerical simulations for once
daily (5 days a week) dosing regimen of Lee 1599 in mice. ........................69

xii

Figure 4-13. Time kill curves calculated from 1000 numerical simulations for twice
daily (5 days a week) dosing regimen of Lee 1599 in mice. ........................70
Figure 5-1. A representation of in vitro PK/PD model set up for dynamic time-kill
studies. ..........................................................................................................76
Figure 5-2. Model fits of bacterial burden at 24h in static time kill studies for Lee
1599 (A) and RIF (B) to obtain the parameter estimates such as E0,
Emax and EC50. ............................................................................................80
Figure 5-3. Observed effect of combination agent Lee 1599 and RIF. ...........................81
Figure 5-4. Model predicted effect of the combination compound Lee 1599 and RIF. ..82
Figure 5-5. In vitro PK/PD dynamic time kill study for Lee 1599, RIF and its
combination with different doses. ................................................................84
Figure 5-6. The bacterial log reduction with different doses using an in vitro PK/PD
dynamic time kill experiment. ......................................................................86
Figure 5-7. In vivo efficacy trial data showing bacterial burden reduction (log
CFU/mL) in the lungs of M. tb infected mice, N=6 for Lee 1599 and
Lee 1599+RIF, N=5 for RIF. .......................................................................87
Figure 5-8. Comparison of %AUC ratios after the %AUC were normalized with
AUC of control group indicating higher the %AUC ratio, greater the
bacterial killing. ............................................................................................92

xiii

LIST OF ABBREVIATIONS
ABC
AIC
ATCC
AUC
AUCss,0-24
BAL
BCG
BIC
BID
CAP
CFU
CKD
CL
CLCr
CLr
CLSI
Cmax
CSF
CVVHDF
DI
DMEM
DPBS
DPM
EBA
ELF
EMA
F
fe
FICI
fup
GFR
HAART
HDA
HFIM
HIV
IC50
II
Imax
IV
LC-MS/MS
LDA
M&S
MDR

ATP binding cassette
Akaike information criterion
American type culture collection
Area under the curve
Area under the curve at steady state plasma concentration
Bronchoalveolar lavage fluid
Bacillus calmette–guérin
Bayesian information criterion
Twice daily
Community acquired pneumonia
Colony forming unit
Chronic kidney disease
Clearance
Creatinine clearance
Renal clearance
Clinical laboratory standards institute
Maximum plasma concentration
Cerebrospinal fluid
Continuous venovenous hemodiafiltration
Deionized water
Dulbecco's modified eagle's medium
Dulbecco's phosphate-buffered saline
Disintegrations per minute
Early bactericidal activity
Epithelial lining fluid
European medicines agency
Oral bioavailability
Fraction excreted unchanged in the urine
Fractional inhibitory concentration index
fraction unbound in plasma
Glomerular filtration rate
Highly active antiretroviral therapy
High dose aerosol
Hollow fiber infection model
Human immunodeficiency virus
Concentration required to produce half-maximal effect
Interaction index
Maximum bacterial kill rate
Intravenous
Liquid chromatography-mass spectrometry
Low dose aerosol
Modeling and simulations
Multi drug resistant

xiv

MIC
MPC
MRSA
MRT
M. tb
NAT2
NCA
NDA
OD
PB
PBPK
PCP
PD
PK
PK/PD
PO
PTA
Q6h
Q8h
QD
RIF
RSE
SEM
SNP
SP
ST
TB
TID
TR-TB
US FDA
USP
VPC
Vss
VUP
WHO
XDR
%SCLSI
%SPD
-2LL

Minimum inhibitory concentration
Mutant prevention concentration
Methicillin-resistant Staphylococcus aureus
Mean residence time
Mycobacterium Tuberculosis
N-acetyl transferase-2
Non compartmental analysis
New drug applications
Optical density
Protein binding
Physiologically based PK and PK/PD modeling
Pneumocystis carinii pneumonia
Pharmacodynamic
Pharmacokinetic
Pharmacokinetics/Pharmacodynamics
Per oral
Pharmacodynamic target attainment
Once every 6 hours
Once every 8 hours
Once daily
Rifampicin
Residual standard error
Standard error of mean
Single nucleotide polymorphisms
Spectinomycin
Streptomycin
Tuberculosis
Thrice daily
Totally drug resistant tuberculosis
United states food and drug administration
United states pharmacopoeia
Visual predictive check
Volume of distribution at steady state
Volume under the plane
World health organization
Extremely drug resistant
CLSI susceptibility breakpoints
Between-subject variability to define PD derived breakpoints
-2 log likelihood

xv

CHAPTER 1.

APPLICATION OF PHARMACOMETRICS IN THE CLINICAL
DRUG DEVELOPMENT OF ANTI-INFECTIVES*
Introduction

With the increased emergence of anti-infective resistance in recent years, much
focus has recently been drawn to the development of new anti-infectives and the
optimization of treatment regimens and combination therapies for established
antimicrobials. In this context, the field of pharmacometrics using quantitative numerical
modeling and simulation techniques has in recent years emerged as an invaluable tool in
the pharmaceutical industry, academia and regulatory agencies to facilitate the integration
of preclinical and clinical development data and to provide a scientifically based
framework for rationale dosage regimen design and treatment optimization. The
following chapter highlights the usefulness of pharmacometric analyses in anti-infective
drug development and applied pharmacotherapy with select examples.
Pharmacometrics in Anti-infective Drug Development
The increased emergence of multidrug resistant (MDR) microbial strains in recent
years and the resulting complications in the clinical care for infected patients is a strong
reminder for the urgent need to develop new anti-infective agents. As the battle against
drug-resistant microorganisms rages on in clinical centers around the globe, the
development of novel single agent and combination therapies against microbial infections
has challenged research scientists in the pharmaceutical industry and academia as well as
clinicians and other healthcare providers to seek a multi-disciplinary approach; one that
encompasses microbiology, clinical expertise, and drug development sciences.
Pharmacometrics has in this context arisen as a formidable tool to bridge and link
between key concepts in these disciplines and to provide a rationale, scientific framework
throughout the drug development continuum as well as in clinical applications [1, 2].
There are case studies which suggest that basing optimization of treatment on
pharmacometric assessments improves the risk-management of MDR pathogens in the
clinical realm by minimizing the failures and mistakes associated with inappropriate or
careless use of antibiotic therapies [3, 4].
Pharmacometrics is the scientific discipline that uses mathematical models based
on biology, pharmacology, physiology, and disease for quantifying the interactions
between drugs and patients (Figure 1-1). Data and information from various sources are
bridged together and quantitatively related to each other. Computer-based modeling and
simulation of pharmacokinetic (PK) and pharmacodynamic (PD) data (denoted as PK/PD
M&S) usually forms the basis for a pharmacometric analysis, but is frequently
-------------------* Adapted with permission. Ashit Trivedi, Richard E. Lee, and Bernd Meibohm. (2013).
Applications of pharmacometrics in the clinical development and pharmacotherapy of
anti-infectives. Expert Review of Clinical Pharmacology, 6(2), 159-170.

1

Figure 1-1. Illustration of interplay of pharmacology, microbiology, physiology,
disease and their association with pharmacometric evaluations in the clinical
development and application of anti-infectives.

2

supplemented by models characterizing important other aspects of drug efficacy and/or
safety in a given situation, such as disease progression, adherence to therapy or bacterial
growth and infection [5]. PD measures used in pharmacometrics are frequently
biomarkers, but can also be surrogate endpoints or clinical endpoints.
Pharmacometrics is aimed at establishing models that provide guidance and
decision support in drug development such as trials design, efficacy comparisons, dosage
regimen optimization and endpoint analysis, but also in supporting regulatory decisions
and improving clinical care in specific patient populations [6, 7]. Its purpose is thereby to
reduce cost and shorten development time by optimizing the clinical assessment of
efficacy and safety.
An increased application of pharmacometric methodologies in drug development
and applied pharmacotherapy has in the last decade been strongly promoted by industry,
academia and especially regulatory agencies, with specific emphasis from the U.S. Food
and Drug Administration [8, 9]. Pharmacometrics has been extensively used in the
development and application of novel antibiotics [10-12]. In addition, increasing
emphasis is more recently being placed on dose selection of approved antibiotics already
in clinical use, with heavy reliance on quantitative benefit-risk evaluations [13].
This chapter aims to provide an overview on the usefulness and utility of
pharmacometrics and in specific modeling and simulation approaches (M&S) in antiinfective drug development and clinical application (Table 1-1), and will highlight these
in examples on the application of M&S approaches in three specific areas:
1. The determination of PK/PD indices and susceptibility breakpoints indicative of
anti-microbial activity in clinical populations.
2. The development of optimal dosing regimens for effective and safe anti-microbial
therapy in both general and specialized population groups, such as pediatric
patients.
3. The optimization of key attributes of study design in clinical development and
postmarketing evaluations.
Prerequisites for the Application of Pharmacometrics
One of the major prerequisites for the application of M&S in clinical drug
development and applied pharmacotherapy is the availability of a mathematical
framework that captures the dose-exposure relationship for the antibiotic in relevant
tissues of interest (i.e. the plasma and tissue pharmacokinetics), the growth characteristics
of the pathogen and its relevant subpopulations in the in vivo environment
(microbiology), and the dynamic interplay between pathogen and antibiotic exposure
with regard to pathogen survival, death, latency or resistance (pharmacodynamics).
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Table 1-1.

Drug

Examples of the application of pharmacometrics analyses for anti-infectives.

Organism

Disease

Target site

Biapenem

Gram positive
and gram
negative
anaerobes

Continuous
venovenous
hemodiafiltration
(CVVHDF)

Plasma and
filtratedialysate

Cefditoren

Streptococcus
pneumoniae

Lower respiratory
tract infections

Plasma and
BAL

Cefepime

Streptococcus
pneumoniae

Extracerebral
infections

Serum and
CSF

Ceftobiprole

Staphylococcus
aureus

Staphylococcal
pneumonia

ELF, serum,
BAL

Staphylococcus
aureus,
Streptococcus
pneumoniae

Nosocomial
pneumonia

Skin, Plasma

Objective for
performing
pharmacometrics
analysis
Determine
appropriate dosage
recommendation
for patients on
CVVHDF
PD profiling &
determining PTA
(Dose: 400mg QD,
oral)
PD profiling &
determining PTA
(2g BID, 0.5h IV
infusion)
PD profiling &
determining PTA
(500mg, TID, 2h
IV infusion)
PD profiling &
determining PTA
& renal dose
adjustments (500
mg BID, 1h
infusion; 500mg
TID, 2h infusion)

4

Outcome

Population

Ref.

300mg BID,
intravenous (2 h
infusion)

Adult Japanese
(mean 65.1 yr),
N=7

[14]

PTA with 33%
T>MIC is <80% for
MIC = 0.06mg/L

Adult Caucasian
(35-78 yr) N=24

[15]

PTA in CSF with
50% T>MIC is
91.8%, 100%
T>MIC is 82%
PTA with T>MIC is
15% for 1-log10
CFU/g reduction;
25% for 2-log10
CFU/g reduction
With 500mg, BID:
PTA of 30% and
50% T>MIC
exceeded 90%. With
500
\mg, TID: PTA of
40% and 60%
T>MIC exceeded
90%.
500mg, BID is
optimal dose for
CLCr ≤ 50mL/min

Adult females
(mean 58.9 yr)
N=7

[16]

Adults (>18 yr)
N=25

[17]

Adults, N=150

[18]

Table 1-1.
Drug

(Continued).
Organism

Disease

Ceftriaxone

Streptococcus
pneumoniae

Extracerebral
infections

CSF

Garenoxacin

Streptococcus
pneumoniae

Communityacquired
pneumonia (CAP)

Serum, ELF

Streptococcus
pneumonia,
Staphylococcus
aureus,
Klebsiella
pneumonia,
Moraxella
catarrhalis,
Haemophilus
influenzae
Streptococcus
pneumoniae

Pneumonia,
secondary
infection of
chronic respiratory
diseases,
bronchitis,
sinusitis,
otis media,
laryngopharyngitis,
tonsillitis
Communityacquired
pneumonia (CAP)

Streptococcus
pneumoniae

Communityacquired
pneumonia (CAP)

Gatifloxacin

Gemifloxacin

Objective for
performing
pharmacometrics
analysis
PD profiling &
determining PTA
(2g BID, 0.5h
infusion)

Target site

Evaluate exposureresponse
relationship by
population PK/PD
Determine PTA in
serum and ELF

N/A

PD profiling &
determining PTA
at 400mg QD, oral
(young) and 200
mg QD, oral
(elderly)
PD profiling &
PTA in serum and
ELF
(320mg QD, oral)

Serum, ELF
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Outcome

Population

Ref.

PTA is 76% for
50% T>MIC in
CSF;
PTA is 65% for
100% T>MIC in
CSF
fAUC0-24/ MIC90 >
200
400mg QD, Oral
dosing is safe and
adequate for
efficacy
PTA > 95% for
fAUC0-24/ MIC90 is
100 (serum) and
120 (ELF)

Adult females
(mean age 58.9
yr) N=7

[16]

Adults (t18 yr)
N=580

[19, 20]

Adult Japanese
(t18 yr) N=136

[21]

PTA for AUC024/MICall ≥ 30 is
92.3% in young;
91.4% in elderly

Adults
Young (<65 yr)
Elderly (>65 yr)
N=183

[22]

PTA (>95%, or
>99% [23]) for
fAUC0-24/MIC90 is
100 (ELF) and
78.3-88 (Serum)

N/A

[20, 23]

Table 1-1.

(Continued).

Drug

Organism

Disease

Escherichia coli,
Chlamydia

Prostatitis

Levofloxacin

Prostatic
tissue

Organisms
causing
Pneumonia

Nosocomial
pneumonia

Plasma, ELF

Metronidazole

Bacteroides
fragilis

N/A

Plasma and
urine

Moxifloxacin

Streptococcus
pneumoniae

Communityacquired
pneumonia
(CAP)

Serum, ELF

Norvancomycin

Staphylococcus
aureus

Gram-positive
bacterial
infections

Serum

Objective for
performing
pharmacometrics
analysis
Determine
penetration at site
of action (500mg
QD)
Determine
penetration ratio in
ELF (500mg QD;
750mg QD)
PD profiling &
determining PTA
at 500mg, TID;
1000mg QD;
1500mg QD
PD profiling &
determining PTA
(400mg QD, 1h
infusion)

Target site

PD profiling &
prediction of CL
estimates in
population (400mg
QD, intravenous)
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Outcome

Population

Ref.

AUCprostrate/AUCplasma
is 2.96

Adult (47-94 yr)
N=22

[24]

AUCELF/AUCplasma is
1.16

Adult (> 18 yr)
N=24

[25]

PTA for AUC/MIC
≥70 is 99%

Adults males,
N=18 (10
healthy, 8
patients)

[26]

PTA (>95%) for
fAUC0-24/ MIC90 is
120 (ELF) and 78.388 (Serum);
Cmax/MIC90 >10,
AUC/MIC90 ~ 100
95% cured clinical
outcome with AUC024/MIC of 579.9
CL=2.54(CLCr/50) in
patients with renal
dysfunction
CL=6.0(Body
Weight/60)0.52 in
healthy subjects

Adults (18-80
yr) N=16

[20, 27]

Adult, N=166

[28]

Table 1-1.

(Continued).

Drug

Organism

Disease

Oseltamivir and
Oseltamivir carboxylate
(OC)

Influenza A
(H1N1 virus)

Influenza A
and B

Serum

Piperacillin/Tazobactam
(combination)

Escherichia
coli, S. aureus,
Klebsiella
pneumonia,
Pseudomonas
aeruginosa,
Bacteroides
fragilis,
Acinetobacter
baumannii
Mycobacterium
tuberculosis

Gram-negative
bacterial
infections

Serum

To determine
PK/PD parameters
& in vivo
effectiveness with
doses 3.375g,
Q4h, Q6h;
4.5g, Q6h, Q8h
(intravenous,0.5h
infusion)

T>MIC is >60% for
all doses

Tuberculosis

Plasma, ELF,
BAL,
Alveolar
Cells (ACs)

Determine
pulmonary PK/PD
in lungs &
evaluate
recommended
dose (600mg, QD,
oral)

Cmax/MIC ≥ 175 are
95% (ACs), 48.8%
(plasma), 35.9%
(ELF); AUC024/MIC ≥ 271 is
100% (plasma);
Higher doses (1200
mg) required as
pulmonary
concentration is too
low with
recommended
dosing

Rifampin

Target site

Objective for
performing
pharmacometrics
analysis
To determine
dosing in neonates
and infants
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Outcome

Population

Ref.

3mg/kg, BID, Oral
in infants 1.7mg/kg,
BID, Oral in
neonates

Adult males
N=6;
Infants (<2 yr)
N=43;
Neonates (1.517.5 weeks)
N=20
Adult males
N=12

[29,
30]

Adults, N=40

[33]

[31,
32]

Table 1-1.

(Continued).

Drug

Organism

Disease

Target site

Telavancin

Staphylococcus
aureus

Health care
associated
pneumonia

Plasma and ELF

Vancomycin

Staphylococcus
aureus

Ventilatorassociated
pneumonia

Plasma,
Bronchoalveolar
lavage fluid,
ELF

Voriconazole

Candida strains

N/A

Plasma

Objective for
performing
pharmacometrics
analysis
To determine
penetration in ELF
with 10mg/kg QD
(intravenous, 1h
infusion)
To determine
penetration in ELF
with 1000mg BID
(intravenous)
To investigate the
effect of
concomitant
fluconazole on
Voriconazole PK
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Outcome

Population

Ref.

AUCELF/AUCplasma
is 0.73

Adult
Caucasians,
N=20

[34]

AUCELF/AUCplasma
is 0.675
AUC/MIC ≥ 400

Adults (>18
yr)
N=10

[35]

Coadministration
is not
recommended,
Monitor for
adverse events if
voriconazole is
sequentially
administered after
fluconazole

Adult males
(21-55 yr)
N=10

[36]

Relevant PK and PD parameters may be derived from a variety of sources,
including preclinical and clinical pharmacokinetic studies, studies assessing tissue
concentration-time courses with techniques such as imaging or microdialysis, in vitro
MIC data, in vitro time-kill curves, disease pathology, and microbiologic characteristics
of the pathogen/infective agent itself [37, 38]. These data can be combined with
knowledge about the between- and within-subject variability in relevant PK parameters
as well as microbiologic differences among different pathogen strains. Since betweensubject variability is oftentimes a major complicating factor in drug development and
pharmacotherapy, the potential impact of M&S approaches is usually higher the larger is
the between-subject variability. The resulting models help identify optimal drug
concentrations necessary to achieve at the target site to be efficacious in overcoming an
infection (i.e. bacterial eradication) and minimizing bacterial resistance, and the
corresponding dosing regimens that provide a high likelihood of therapeutic success in a
specific target population [10, 39]. Once this basic framework has been established,
additional factors including human physiological, biochemical, and genetic variability
and differences to preclinical species that complicate the translation of preclinical results
to the clinic and of data from controlled clinical studies to clinical practice may be
considered and implemented in the modeling framework.
PK/PD Indices and Susceptibility Breakpoints
Susceptibility breakpoints, or critical antimicrobial concentrations, are valuable
parameters in assessing the degree of drug susceptibility and/or resistance to an
antimicrobial pharmacotherapy. Breakpoints refer to antibiotic concentrations or
exposures that separate bacterial strains where there is a high likelihood of treatment
success from those bacteria where treatment is more likely to fail. Historically,
pharmacokinetic exposure parameters such as the area-under-the-plasma-concentrationtime-curve (AUC) or the maximum or peak concentration (Cmax) have been the gold
standard for monitoring drug action under the assumption that plasma concentration are
indicative of target site concentrations and that a defined and fixed target site exposure is
necessary for drug action. For antimicrobial pharmacotherapy, however, target site
exposure is not sufficient to predict efficacy since the susceptibility of the microorganism
to the target site concentration is variable among different microorganisms and strains
and may change over time in the event of for example resistance development.
Susceptibility of a microorganism to an antibiotic is frequently described by its minimum
inhibitory concentration (MIC), an in vitro parameter that quantifies growth inhibition to
a static antibiotic concentration. Combination of the pharmacodynamic parameter MIC
with pharmacokinetic exposure parameters such as AUC or Cmax allows defining PK/PD
indices that are hybrid parameters that integrate PK and PD information related to target
exposure and microbial sensitivity, and can be used to derive PK/PD breakpoints.
Dependent on the predominant mechanism of action of the antibiotic, the following three
PK/PD indices (as shown in Figure 1-2) have been found useful in characterizing in vivo.
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Figure 1-2. Illustration of the PK/PD indices at steady state during multiple
dosing: (i) T>MIC: Time above MIC (ii) Cmax/MIC (iii) AUC/MIC.
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1.

T > MIC: Time T of exposure of microorganisms to plasma concentrations
exceeding its MIC.

2. Cmax/MIC: Ratio of peak plasma concentration to MIC.
3. AUC/MIC: Ratio of area under plasma concentration curve to MIC.
These indices are frequently used to classify the pattern of killing activity for
antimicrobials, concentration-dependent vs. time-dependent. Antibiotics for which T >
MIC best describes their antimicrobial activity follow time-dependent killing with
minimal persistent effects that requires a maximum duration of exposure above MIC for
maximum activity. Antibiotics for which Cmax/MIC best describes their antimicrobial
activity follow concentration-dependent killing with prolonged persistent effects that
require a maximum peak antibiotic concentration for maximum activity. Antibiotics for
which AUC/MIC best describes their antimicrobial activity exhibit both time-dependent
and concentration-dependent killing with moderately persistent effects that require a
combination of high concentration and long duration above MIC for maximum activity.
The AUC in these indices is calculated at pharmacokinetic steady state over 24h
(AUCss,0-24) and is usually derived from Bayesian parameter estimates from population
PK analysis approaches.
As indicated in these relationships, the MIC is consistently used as a denominator
or ‘normalization factor’. The integration of drug exposure (PK) and the actual drug
activity based on microbial sensitivity (PD) allows to develop generalized breakpoints
with which multiple drugs can be evaluated for efficacy related to both their PK and PD
parameters [40-42]. The efficacy is the desired clinical effect that a particular drug is
producing and is the combined effect of PK and PD and other, for example patientrelated, factors. The term ‘efficacy’ cannot be interchanged for PD. Thus, breakpoints
are often used as a valuable tool in drug development and applied pharmacotherapy to
optimize dosing regimens of an antibiotic for the treatment of a specific pathogen and to
minimize the increase of resistant strains with optimal dosing.
It should be stressed, however, that many antibiotics are bound to variable degree
to proteins in plasma and tissue, and that only the free, unbound concentration at the
target site is pharmacologically active and exerts the antimicrobial activity. Since MIC is
frequently determined with no or limited binding proteins present, it usually represents an
unbound concentration [43]. Thus, PK/PD indices also need to be based in free drug
exposures rather than total concentrations to avoid any bias introduced by considering
protein binding only in the PD parameter MIC, but not the PK parameters AUC and
Cmax. Consequently, fT>MIC, fCmax/MIC, and fAUC/MIC based on free drug
concentrations are now usually applied as appropriate PK/PD indices [40-42, 44].
PK/PD indices assessed in M&S studies can be used to assess and compare the
likelihood of achieving effective target exposure for different antibiotics and thus
prioritize compounds for the treatment of specific infections. Noreddin et al. used this
approach by applying simulation studies to determine the probability of target attainment
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in serum and epithelial lining fluid (ELF) defined as a fAUC0–24/MIC90 ratio of 30, with
bacterial eradication as efficacy endpoint, for standard clinical regimens of azithromycin,
clarithromycin, and telithromycin against S. pneumonia strains with different
susceptibility [45].
Another example for establishing PK/PD indices by M&S is the case of isoniazid
which displays a multimodal elimination pattern in the population based on single
nucleotide polymorphisms (SNPs) in the gene encoding for N-acetyl transferase-2
(NAT2). Since the allelic frequency of these genetic variants differs among different
ethnic groups, these groups differ in the number of “slow” and “fast” acetylators based on
NAT2 phenotype. Thus, standard recommended doses would obviously result in different
bactericidal activities among different populations. In vitro models showed that AUC024/MIC is associated with both microbial death and emergence of resistance for
isoniazid. Based on this approach, M&S was used to predict the bactericidal effects of
different doses of drug in various ethnic populations, accounting for the multimodal
elimination of isoniazid. The model allowed to predict the dose with highest early
bactericidal activity (EBA) and this dose was used in subsequent clinical studies [46].
Based on susceptibility breakpoints microorganisms are classified as susceptible,
intermediate and resistant based on predefined. The identification of susceptibility
breakpoints is being performed using standard tests implemented by the Clinical
Laboratory Standards Institute (CLSI) by examining MIC distributions across different
strains of a bacterial species. MIC values are measured using Mueller-Hinton broth, as
recommended by CLSI guidelines [42, 47]. While these test methodologies achieve a
precise estimate of breakpoints in vitro, the major challenge lies in the ability for clinical
translation. Since target site exposure and microbial susceptibility will vary among
different individuals with different infection sites and different pathogen populations,
susceptibility breakpoints are inherently variable in a clinical population [40]. Thus, in
vitro derived breakpoints have to be interpreted as point estimates in a breakpoint
distribution with a confidence interval that presents itself in the clinic [48]. M&S
approaches using clinical data may contribute to derive and increase the exactness or
confidence in the derived breakpoints.
Multiple studies have indicated inconsistencies between the probability of PD
target attainment (PTA) and susceptibility as per CLSI defined breakpoints. DeRyke et al.
demonstrated that CLSI susceptibility breakpoints (%SCLSI) overestimated probability
for achieving bactericidal exposure for antibiotics such as ciprofloxacin, levofloxacin and
piperacillin-tazobactam against gram negative bacteria such as P.aeruginosa, A.
baumannii, E. coli and Klebsiella spp. [48]. To overcome this limitation, the authors used
Monte-Carlo simulations based on published PK data and their between-subject
variability to define PD derived breakpoints (%SPD). This %SPD accounts for betweensubject variability in human pharmacokinetics as well as exposure differences resulting
from different dosing regimens. In this approach, %SPD was defined as the highest MIC
at which at least 90% of the population achieve the targeted bactericidal exposure, and
bactericidal exposure was defined as fT>MIC (time of free concentration above MIC) of
40% for carbapenems, 50% for cephalosporins and the piperacillin component of the
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piperacillin-tazobactam combination, and 125 for the AUC/MIC ratio of
fluoroquinolones. The analysis indicated that although there was a general lack of
agreement between PTA and %SPD or %SCLSI, only %SCLSI overestimated the ability
of the investigated dosing regimens to achieve bactericidal exposures. In contrast, %SPD
often underestimated PTA, a deviation clinically far less concerning than overestimation.
The underestimation of PTA using %SPD leads to an overestimation of dose in a
particular subject (which is preferable), but the general overestimation of doses for a
population can lead to an increase in bacterial resistance. Based on the performed
simulations, the authors suggest pathogen and dosing regimen specific breakpoints as a
more appropriate way to classify bacteria as susceptible [48].
Development of Optimal Dosing Regimens
One of the top priorities in antibiotic pharmacotherapy is to optimize the duration
of therapy with proper dosing regimens that are effective and safe, and minimize the
occurrence of bacterial resistance. However, these goals are often requiring opposing
measures and can often not be achieved simultaneously. The concept of clinical utility
can help in optimizing these goals. Clinical utility allows to quantify and optimize “tradeoffs” between multiple factors such as efficacy, safety, microbiology, and usage of drugs
[49]. Pharmacometrics allows the integration of clinical utility with M&S, where “tradeoffs” can be derived and explored mathematically.
The clinical efficacy (i.e. bacterial eradication) of drugs such as garenoxacin,
telithromycin and doripenem is more than 90%. With such high efficacy it is challenging
to design dosing regimens on the basis of efficacy and safety at varying doses. Population
based pharmacokinetic M&S using Monte Carlo simulations helped in deciding on a
dosage regimen by taking into account the between-subject variability in PK parameters
and varying MIC distributions by various clinical isolates. This approach helped in
determining the optimal dose for garenoxacin (400mg) on the basis of:
1. Selecting AUC0-24/MIC as an appropriate PK/PD index derived from in vivo
efficacy data
2. Performing Monte Carlo Simulations using population PK parameters, MIC
distributions and mutant prevention concentration (MPC)
3. Determining a recommended dose based on probability of target attainment
4. Validation of the recommended dose based on PK/PD data acquired from phase
III studies for respiratory tract infection [21].
Design of dosing regimens is especially challenging for patients who are critically
ill with severe bacterial infections, and who have renal failure and are on continuous
venovenous hemodiafiltration (CVVHDF). In the event of renal failure, dosing regimen
needs of individual patients can be adjusted by assessing the impact of kidney
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dysfunction on the disposition of drugs [50]. For example the PK and PD properties of
biapenem change when a patient is on CVVHDF. Ikawa et al. performed PK M&S to
determine PD exposure of T>MIC4μg/mL and suggested that for T>MIC4μg/mL for 30% of
the dosing interval biapenem dosage should be 300mg BID, 600mg BID, or 600mg BID
for dialysate flow rates of 1.4L/h, 2.8L/h, or 5.6L/h, respectively [14]. As the dialysate
flow rate increased, T>MIC4μg/mL decreased. The 600mg BID dose was the optimum to
reach T>MIC4μg/mL of 30% for both dialysate flow rates of 2.8L/h and 5.6L/h. These
simulations illustrate that low doses or increased dosing intervals should not be
recommended for patients who are on CVVHDF or renal replacement technique.
Since critically ill patients often have altered drug distribution and elimination,
they may experience inadequate dosing with antibiotics and may thus be at a much higher
risk of infections with antibiotic resistant organisms [51]. For doripenem, a carbapenem,
T>MIC for 35% of the dosing interval has been the recommendation in patients with
normal kidney function. Since doripenem is primarily excreted in unchanged form into
the urine, PK-based Monte Carlo simulations were performed to develop dosing
recommendations for patients with renal impairment. For mild-stage 2 chronic kidney
disease (CKD) patients with a creatinine clearance (CLCr) >60mL/min, 500mg should be
infused over 1h every 8h for bacteria with MIC ≤1μg/mL; however, in the more severe
stage 3 CKD patients with CLCr ~30-50mL/min, an infusion of 250mg of doripenem over
1h every 8h for bacteria with MIC ≤2μg/mL is recommended. For patients with severe
renal impairment with a CLCr of 10-29mL/min, 250mg was recommended to be infused
over longer durations, 4h instead of 1h, every 12h for MIC ≤2μg/mL. This is consistent
with the time-dependent (T>MIC) killing pattern of carbapenems. Dosing strategies like
this can only be achieved from PK/PD M&S where the creatinine clearance builds the
parameter framework for achieving set exposure levels, as PK studies in critically ill
patients would be extremely difficult to perform [52].
In order to be efficacious, an antibiotic needs to reach the site of infection in
therapeutically effective concentrations. In patients with severe lung infections, the
concentration of antibiotics in ELF is an essential measure to decide on an optimal
dosage regimen [25]. It has been reported recently that methicillin-resistant S. aureus
(MRSA) is the likely culprit in causing more than 25% of all ventilator-associated
pneumonias in intensive care unit patients [53]. A population PK model with Monte
Carlo simulations was employed to determine the range of ELF exposure relative to that
in plasma. It was determined that vancomycin penetrates ELF at approximately 50% of
plasma concentrations [35]. Under the assumption that the PK/PD in ELF is similar to the
AUC/MIC of ≥400 used in plasma, the M&S exercise showed that target attainment is
expected to be suboptimal for MRSA with MICs in excess of 1 mg/L under current
dosing regimens. A similar approach was used for PD profiling of cefditoren and
telavancin against penicillin-susceptible and penicillin-intermediate S. pneumonia [15]
and methicillin-resistant S. aureus, respectively [34].
The MIC value for an antibiotic varies depending on which organism it acts upon.
Carbapenems require higher MIC to be effective against P. aeruginosa as compared to
other bacteria. The antibacterial efficacy of four commonly used dosage regimen for
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doripenem was determined using an integrated PK/PD M&S approach based on in vitro
time-kill data and human PK data. The simulations indicated time-dependent
antimicrobial activity of doripenem, in which the 250mg TID regimen had a higher
bactericidal effect than did 500mg BID [54].
While dosage regimens for most antibiotics can be derived by PK/PD-based M&S
as outlined in the presented examples, the therapeutic concentration obtained from those
recommendations may be insufficient to safeguard optimum clinical efficacy and
bacterial clearance from the site of infection, especially if they are based on studies in
healthy individuals rather than patients. Hence, it is of utmost importance to take into
account the disposition (PK) and target site accessibility of antibiotics in diseased
individuals having abnormal physiological conditions such as renal dysfunction. Along
these lines, it is often preferred to use in these PK/PD M&S evaluations drug resistant
bacteria that constitute a worst case scenario. An example for such an approach is the
dose optimization of norvancomycin against methicillin-resistant rather than non-resistant
Staphylococcus isolates for patients with different physiological and pathological
conditions in the Chinese population. The optimized norvancomycin dosing
recommendations were 800-1000mg BID for patients with normal renal function, 800mg
QD or BID for patients with mild renal dysfunction (CLCr >50 to ≤ 85mL/min), 800mg
QD to 2.5days for patients with modest renal dysfunction (CLCr >10 to ≤ 50mL/min), and
600mg over 5-11days or 800mg over 6-13days for patients with severe renal dysfunction
(CLCr >5 to ≤ 10mL/min) [28].
Optimization of Clinical Studies and Clinical Applications
Over the last decade, it has become obvious in many examples that fine tuning of
phase II/III clinical trials as well as post-marketing studies a priori is essential to reduce
cost and optimize study performance and outcomes. PK/PD based M&S has played a
major role in this process by integrating observations and data obtained from preclinical
studies in animals and phase I studies in healthy volunteers as well as phase IIa studies in
patients. The factors taken into consideration for mathematical modeling are often:
1. MIC distribution patterns in clinical isolates
2. The range of individual PK parameters in the target patient population
3. Identified PD targets from efficacy studies in animals
4. The degree of protein binding.
The combination of microbiological, preclinical and clinical PK and PD data in
mathematical models is essential in designing target antibiotic exposures. M&S with such
data is not only beneficial for single drug therapy but also for the evaluation of multiple
concurrently used antibiotics and their potential additive or synergistic effects [41].
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There is a sustained need for monitoring the PK/PD of antibiotics even after their
approval and marketing. Rifampin is widely used for treatment of tuberculosis since
several decades, but there is only limited data on rifampin concentrations in the lungs.
Using an M&S based simulation study, Goutelle et al. found that the existing dosage
regimen (600mg/day) for rifampin is suboptimal in most patients. This could be a
potential contributing factor for the increasing number of tuberculosis infections with
multi drug-resistant and extremely drug-resistant strains. The authors suggest considering
higher doses (1200mg/day) of rifampin for an increase in pulmonary concentrations,
thereby keeping in mind the toxicity and tolerability of such high doses in patients [33].
M&S may also be useful in developing strategies to minimize the effect of drugdrug interactions. Voriconazole and fluconazole are two widely used antifungal drugs
with similar mechanism of action, but a strong drug-drug interaction when immediately
switching between the two agents. Fluconazole is the most commonly used antifungal
agent but unlike voriconazole it does not have anti-aspergillosis coverage sometimes
necessitating a clinical switch. Fluconazole is a CYP2C19 inhibitor and its presence
inhibits voriconazole metabolism causing substantial voriconazole-related adverse
effects. Physiologically based PK modeling was used to determine the time lag required
between the two therapies to avoid potential toxicity, but also minimize the time period
without effective antifungal exposure which is essential in the event of serious fungal
infections. The PK simulations demonstrated that a time lag of at least 24h is required to
switch from fluconazole to voriconazole in order to avoid relevant interactions [36].
The use of M&S is not only restricted to optimizing dosing regimen and efficacy
of treatment, but can also be used for building up clinical treatment guidelines. Goldie et
al. constructed a population model of HIV infection to answer lifetime cost, life
expectancy, quality-adjusted life expectancy, and quality-adjusted life years in patients
receiving highly active antiretroviral therapy (HAART) and Pneumocystis carinii
pneumonia (PCP) prophylaxis. The simulation exercises were performed to compare
different criteria of CD4 cell counts for discontinuing primary PCP prophylaxis in
patients with CD4 cell count increases receiving HAART and second-line PCP
prophylaxis (such as dapsone, atovaquone, and aerosolized pentamidine) due to
intolerance to trimethoprim-sulfamethoxazole. The outcome of the exercise showed that
treatment is cost-effective when PCP prophylaxis is discontinued with CD4 count
>300/μL, and that in patients intolerant to trimethoprim-sulfamethoxazole dapsone
therapy is more cost-effective than atovaquone [55].
Future Prospects
The application of pharmacometric analyses using PK/PD based M&S approaches
has in the recent decade developed into one of the most essential tools for interpreting
and integrating large and diverse pools of preclinical and clinical data and translating
them into an informative knowledgebase [5]. It is expedient not only for industry
professionals to promote internal decision making at critical drug development steps, but
is also increasingly utilized by regulatory authorities for compiling and analyzing data for
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approval and labeling. A recent survey shows that during the last decade, the drug
approval and labeling decisions of more than 60% of submissions for New Drug
Applications (NDA) to the US FDA were influenced by pharmacometric analyses. For
30% of the submissions during this period, FDA reviewers performed independent
pharmacometric analysis [13]. For example, among anti-infectives, an appropriate dosing
regimen of micafungin for the treatment of esophageal candidiasis was selected based on
an exposure-response analysis by FDA personnel. The FDA reviewers utilized the phase
II and III study data to model the relationship between dose and effectiveness, which led
them to recommend approval of the 150mg over the 100mg micafungin dose due to
similar maximum efficacy, but a 15% lower rate of relapse [9].
Another prime example for use of M&S in regulatory decision making is the
pharmacometrics-based dose selection of levofloxacin for post exposure treatment of
inhalational anthrax in children. The available data from two PK studies on 47 adults at
different doses (500mg/kg and 750mg/kg) and 90 pediatric patients who received a dose
of 7mg/kg were used to develop an integrated population PK model. The model was then
utilized to derive dosing recommendations for pediatric patients that match adult
exposure after a 500mg/kg dose with regard to AUC, and maximum and minimum
concentration during multiple dosing at steady state. Based solely on this M&S approach,
a dose regimen of 8mg/kg BID for children <50kg and ≥ 6months of age and 500mg QD
for children weighing ≥50kg was recommended and included in the labeling information
[56].
The US FDA and the European Medicines Agency (EMA) both acknowledge the
impact of M&S on regulatory approvals, but assess the investigational plans and
scientific information differently. FDA seems to prefer to conduct pharmacometric
reviews including independent data analyses for all the submitted applications
irrespective of whether the sponsor submitted an analysis or not. In contrast, EMA seems
to consider a pharmacometric assessment only if it is included in the submission by the
sponsor. EMA might ask for additional pharmacometric analyses, but these should be
conducted by the sponsor. European regulatory bodies are especially encouraging and
emphasizing the use of M&S for drugs in pediatrics and for anti-infectives [57-59].
Irrespective of these different philosophies in the review process, the emphasis and
demand of M&S based pharmacometric analyses in drug approval will likely further
increase the application of M&S throughout the drug development process [8, 30, 60].
More recently, physiologically based PK and PK/PD modeling (PBPK) is gaining
more widespread application, predominantly because of improvements in the associated
M&S methodologies and the availability of more robust and user-friendly software tools
[61-63]. It is predicted that the use of PBPK will increase over the next years for
identifying the effects of intrinsic and extrinsic factors modifying drug efficacy and
safety in patients. PBPK will play a significant role in predicting and deciphering drugdrug interactions and will be the basis for M&S in special population such as pediatric
patients or in critically-ill patients [63].
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Evidently, pharmacometric analyses have proven their merits in myriad ways
during the entire process of drug development. However, there is always room for
improvements for more accurate and precise estimates resulting in more confident
predictions. This fine-tuning can likely be accomplished by a more prospective
integration of M&S approaches in each individual development phase, including goaloriented and intelligent sample and data collection that specifically addresses and
supports pharmacometric analyses. Some of the questions that need to be addressed relate
to the transfer of knowledge from controlled studies to clinical practice: PK parameter
estimates are generally derived from healthy subjects. How can we assure that PK/PD
predictions are accurate in patients with variable physiologic function and variable sites
and types of infection? How can we account for patients with multiple disease
conditions? How will their confounding illnesses or polypharmacy affect drug exposure
for the considered anti-infective? How will variability in the strains of microorganisms
and their response to the survival stress elicited by the anti-infective such as latency and
resistance development affect treatment outcome? A more systematic and intensive
assessment of antibiotic concentrations at the site of action such as ELF over the time
course of therapy might help to provide some of the needed answers. Techniques such as
microdialysis have been proven of substantial value in assessing active drug
concentrations in target tissues not as easily accessible as ELF [64, 65].
In summary, more complex M&S models will likely be established in the future
that integrate all therapeutic considerations when treating microbial infections. Using
precise estimates of PK and PD parameters as well as their distributions in populations of
patients and microorganisms, including their potential interdependencies, will help in
facilitating more realistic and thus also even more clinically meaningful predictions for
the in silico evaluation and development of optimal antibiotic dosing regimens, including
combination therapies. To combat the growing bacterial resistance, we need to rapidly
increase the available number of effective antibiotics in our armamentarium by relatively
fast, safe, smart and inexpensive clinical development programs. We believe that M&S
based pharmacometric approaches hold great promise in facilitating this process and thus
may serve as a key technology for the development of future generations of antiinfectives.
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CHAPTER 2.

CENTRAL HYPOTHESIS

Among the most deadly infectious microorganisms, tuberculosis is a second
greatest killer worldwide [66]. According to WHO [67], tuberculosis kills approximately
1.5 million people annually and it was estimated that 480,000 patients developed multidrug resistant TB (MDR-TB) in 2013 alone. The existing drug therapies requires
treatment spans of 4-24 months and efficacy is hindered severely by poor adherence to
dosing regiments and drug adverse effects. This alarming situation undoubtedly calls for
the urgent need for the development of novel and more effective treatment options to
defeat TB [68, 69]. The primary goal for current anti-tuberculosis drug development
efforts is to shorten the treatment regimen and circumvent drug-resistance mechanisms.
Our group has designed a novel semi-synthetic series of spectinomycin analogs,
or spectinamides. All compounds in this series were initially screened using in vitro
assays. The results from these preliminary studies aided in refining the chemical structure
of lead compounds and improved their drug-likeness properties for clinical readiness. The
lead optimization process comprised in vitro and in vivo pharmacological,
biopharmaceutical, pharmacokinetic (PK) and pharmacodynamic (PD) profiling of
candidate compounds [70, 71]. Using a pharmacometric approach, we integrated the PK
and PD properties of spectinamides to better characterize the interplay and
interdependencies between drug concentration and drug efficacy in models of disease.
We hypothesized that a pharmacometrics-directed quantitative approach for integrated
PK/PD characterization is useful for antibiotic lead characterization and highly predictive
of in vivo antibacterial efficacy.
Specific Aim 1
In this Aim 1 (Chapter 3), we investigated the biopharmaceutics and
pharmacokinetic properties of select spectinamide agents to determine lead candidate
compounds and provide the basis for pharmacometrics-directed PK/PD assessments. An
important aspect in the efficacy and safety of novel drug candidates is the extent of
distribution and potential accumulation in tissues. In this context, intracellular uptake into
macrophages is a prerequisite for antibiotic activity against M. tb residing inside infected
macrophages. To address these questions, we also evaluated the biodistribution profile of
a radio-labeled spectinamide and cellular uptake of spectinamides into murine
macrophages.
Specific Aim 2
In Aim 2, we further evaluated the PK/PD relationships of lead compound, Lee
1599 using an in vitro PK/PD model system which characterizes a dose-response
relationship in order to facilitate a rational dose-selection for in vivo efficacy trials
(Chapter 4). While PD assessments under static conditions such as MIC determinations
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provided only a point estimate of anti-bacterial activity. A more effective way of
determining the appropriate dosing regimen with optimum efficacy and with high
correlation between in vitro and in vivo efficacy is through an integrated PK/PD model
approach. An in vitro PK/PD model is a convenient tool to predict the efficacy, dosing
regimen of single or combination drug candidates and PK/PD indices (concentration
and/or time dependent killing) based on dynamic time-kill curves for supporting in vivo
studies. To test this hypothesis we determined the time-kill effect of Lee 1599 at various
dosing regimens against M. bovis BCG as model organism. With this data, we developed
a PD model to describe Lee 1599 mediated bacterial killing. Based on these in silico
simulations, we were able to predict the optimal dosing regimen for in vivo efficacy
studies.
Specific Aim 3
In Aim 3 (Chapter 5), we expanded the pharmacometrics-directed quantitative
PK/PD assessment of Lee 1599 to combination therapies with rifampicin as model
compound. Traditionally, qualitative methods such as the checkerboard assay have been
widely used to evaluate possible pharmacodynamic interaction between two agents. We
applied a three dimensional surface response assay as quantitative pharmacometric tool
for characterizing the interaction between Lee 1599 and rifampicin and compared them to
the checkerboard assay. We validated the results of both assays by expanding our
previously applied with an in vitro PK/PD model (Chapter 3) to drug combination
therapy and by a comparison to results of in vivo studies in a mouse model of M. tb
infection.
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CHAPTER 3. PHARMACOKINETICS AND BIODISTRIBUTION OF A
NOVEL SERIES OF ANTI-TUBERCULOSIS AGENTS: SPECTINAMIDES
Introduction
Tuberculosis (TB) is a global pandemic that has a mortality rate of approximately
1.5 million people per year. The existing drug therapy requires treatment for a span of 424 months. The flaws of this treatment regimen become very apparent once it is
administered to patient populations, as it is lengthy and complicated resulting in poor
patient adherence. As a result, many patients discontinue therapy before complete
eradication of the disease, which subsequently may lead to the development of drug
resistant strains such as multi drug resistant (MDR), extremely drug resistant (XDR) and
totally drug resistant tuberculosis (TR-TB) [67, 68, 72-76].
With the help of a structure based design process, novel semisynthetic analogs of
spectinomycin called spectinamides were recently discovered. Spectinamides inhibit
protein synthesis by selectively binding to the head domain of the 30S ribosomal subunit
and blocking its translocation [77]. They have also exhibited overcoming an intrinsic
resistance mechanism by avoiding the tap efflux pump Rv1258c in M. tb. Rv1258c is an
efflux pump belonging to the ABC (ATP-binding cassette) transporters and is known to
play an important role in mediating the efflux of different chemical classes and
antibiotics [78-80]. While spectinomycin is a substrate for Rv1258c resulting in no
relevant activity against M. tb, the structural modification in spectinamides renders them
unsuitable as Rv1258c substrate. Thus, the potency of the spectinamide series is a
product of high affinity for the mycobacterial ribosome and the avoidance of Rv1258c
efflux pumps [81].
The primary goal of this chapter is to gain knowledge of the preclinical
pharmacokinetics of the select compounds in the spectinamide series. We also
investigated the biodistribution properties of a spectinamide lead, Lee 1329, using a
radioisotope technique, as well as uptake into macrophages. Knowledge about the extent
and pattern of biodistribution are crucial PK characteristics that may determine the
efficacy and safety profile of drug candidates.
Materials and Methods
Chemicals and reagents
All tested spectinamides were synthesized in the laboratory of Dr. Richard.E. Lee
at St.Jude Children’s Research Hospital, Memphis, TN, including Lee 1329 (3’-dihydro3’-deoxy-4(R)-(pyridin-2-yl) acetylamino spectinomycin), Lee 1544 (3’-Dihydro-3’deoxy-4(R)-(4-chloropyridin-2-yl) acetylamino spectinomycin), Lee 1599 (3’-Dihydro3’-deoxy-3’(R)- (5-chloropyridin-2-yl)acetylamino spectinomycin Trihydrobromide), 3'-
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Dihydro-3'-deoxy-3'(R)- (4-(4-chlorophenyl)pyridin-2-yl))acetylamino spectinomycin
Trihydrobromide (Lee 1601), 3'-Dihydro-3'-deoxy-3'(R)- (2-(pyridin-2-ylamino)thiazol4-yl)acetylamino spectinomycin Terahydrobromide (Lee 1603), 3'-Dihydro-3'-deoxy3'(R)- (4-chloro-5-fluoropyridin-2-yl)acetylamino spectinomycin Trihydrobromide (Lee
1661), 3'-Dihydro-3'-deoxy-3'(R)- (1-methyl-1H-benzo[d]imidazol-2-yl)acetylamino
spectinomycin Trihydrobromide (Lee 1663) as shown in Figure 3-1. Acetonitrile,
methanol, HPLC grade water, formic acid and ammonium formate were purchased from
Fisher Scientific (Pittsburgh, PA). Drug free rat plasma was purchased from Innovative
Research (Novi, MI).
Protein binding
The plasma protein binding is determined using equilibrium dialysis with ready to
use RED device inserts from Thermo Scientific (Rockford, IL) in base plates containing
plasma and buffer chamber for analysis. High and low concentrations (500ng/mL and
5μg/mL) of test compounds are prepared in rat plasma. 200μL of the plasma sample was
added to the central compartment and 350μL of blank isotonic phosphate buffer, pH 7.4
to the peripheral compartment of dialysis base plate. The base plate is covered with
sealing tape and incubated at 37oC at approximately 100 rpm on an orbital shaker for 4h
to achieve equilibrium. The drug concentration is determined using an LC-MS/MS assay.
The free fraction of the drug is calculated as ratio of the concentrations in the buffer and
in plasma. The results are expressed in terms of %-bound to plasma proteins.
Formulation preparation and administration
Spectinamides (10mg/kg and 100mg/kg) were formulated in plasmalyte solution
and sterilized by filtration (0.2 micron syringe filter). The IV doses were administered via
femoral vein catheter followed by flushing the catheter with locking solution. A group of
5 rats were dosed for each compound and dose level.
Pharmacokinetic studies
The PK studies are performed on catheterized (jugular vein alone for oral study
(PO) and jugular vein and femoral vein for intravenous (IV) study) male Sprague-Dawley
rats weighing approximately 225g (8-10 weeks old). The animals were housed in the
animal facility with 12h of light/dark cycle with food and water available ad libitum at
University of Tennessee Health Science Center following protocol number 13-4263A. the
protocol was approved by the Institutional Animal Care and Use Committee at University
of Tennessee Health Science Center. Test compounds were administered for IV and PO
studies at a dose of 10mg/kg and 100mg/kg, respectively. Serial blood samples were
collected pre-dose and at predetermined intervals until 72h. Plasma was separated
immediately by centrifugation at 10,000 rpm, 4oC for 10min and stored at -80oC until
analysis. Plasma and urine samples were analyzed for drug concentrations by
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Figure 3-1.

Chemical structure of lead spectinamides with MIC values.
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LC-MS/MS analysis. Blood samples (250μL) were collected at 0.25, 0.5, 0.75, 1.0, 1.5,
2.0, 4.0, 6.0, 8.0, 12.0, 24.0, 36.0 and 48.0h after drug administration. Urine samples
were collected at intervals of 0-6, 6-12, 12-24, 24-36 and 36-48h post-dose and stored at 20oC until analysis.
Pharmacokinetic data analysis
The concentration-time profiles for both PO and IV administration were analyzed
by non-compartmental analysis. The IV concentration-time profiles were also analyzed
by nonlinear regression analysis using a 2-compartment open model with bolus input and
first order output. The area under curve (AUCinf) from time zero to infinity was
calculated using the trapezoidal rule by extrapolating to time infinity. Mean residence
time (MRT), defined as the average amount of time a drug particle remaining in a
compartment of a system upon IV administration was calculated using
 ܴܶܯൌ

ܥܯܷܣ
ܥܷܣ

where AUMCinf is the area under the moment curve when the concentration-time curve is
extrapolated to infinity. The systemic clearance (CL) was calculated using the equation
 ܮܥൌ

݁ݏܦ௩
ܥܷܣǡ௩

where Doseiv and AUCinf,iv are the IV dose and area under the plasma concentration-time
curve from time 0 to infinity, respectively. An estimate of volume of distribution at
steady state (Vss) was obtained from IV data using
ܸ௦௦ ൌ ܮܥ כ ܴܶܯ
Oral bioavailability (F) was calculated using
ܨൌ
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where Doseoral, Doseiv, AUCinf, iv, and AUCinf,oral are the oral and IV doses and the
corresponding areas under the plasma concentration-time curves from time zero to
infinity, respectively. Urinary excretion parameters were calculated from the cumulative
dose excreted unchanged in urine and the fraction unbound in plasma (fup). Glomerular
filtration rate (GFR) was taken from the physiologic parameters published by Davies et al
[82]. The fraction (fe) of the test compound excreted in urine was calculated as the
cumulative amount of dose excreted unchanged in urine divided by the dose of the test
compound administered. Renal clearance (CLr) values were determined from the total
plasma CL and the fraction excreted in urine using fe*CLtotal. The net processes such as
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filtration, reabsorption and secretion a drug undergoes in the kidney can be evaluated
using excretion ratio (Eratio). This was calculated using CLr/(fup*GFR).
Macrophage uptake assay
Uptake of spectinamide compounds (Lee 1329, 1443, 1445, 1544, 1599), SP and
ST into murine macrophages was studied in the J774A.1 cell line (ATCC, Manassas,
VA). J774A.1 cells were cultured in T25 flasks in Dulbecco's Modified Eagle's Medium
(DMEM; Gibco, USA) with 10% Fetal bovine serum (Sigma-Aldrich, USA) and
maintained at 37oC, 5% CO2. Cells were scraped using teflon cell scraper from the T25
flasks and the final cell density of 2 to 4×105 cells/mL was adjusted using fresh DMEM.
The cells were allowed to grow for 48h at 37oC until 60-80% confluent in a 6-well plate
(each plate representing individual time point and concentration). The media was
aspirated from the wells and fresh DMEM containing a final test compound concentration
of 25μg/mL or 100μg/mL was added. The plates were incubated at 37oC, 5% CO2 for
0.5, 1, 4, 8 and 24h. Additional plates were also incubated for 48, 72 and 96h. The media
containing test compound was aspirated at every time point and the cells were washed
with ice-cold Dulbecco's Phosphate-Buffered Saline (DPBS) for three times. The cells
were suspended in 1mL of water and sonicated for 2min. The cell suspension was
centrifuged for 5min at 10,000 rpm and the supernatant collected was used to determine
the drug uptake using LC-MS/MS assay. The drug uptake was expressed in terms of
μL/mg of protein. The protein content in cells was determined using the Pierce BCA
assay kit (Thermo Scientific, Pierce Biotechnology, IL, USA).
Sample preparation and LC-MS/MS analysis
The plasma and urine samples were prepared by the protein precipitation method
by adding 50μL aliquots to 200μL methanol (spiked with the internal standard 3′dihydro-3′-deoxy-3′(R)-isopropylacetylamino spectinomycin) followed by vortexing for
1min, centrifugation at 10,000g for 10min at 4oC. The supernatant was separated via
chromatography on a Luna 3μM hydrophobic interaction liquid chromatography (HILIC)
100 × 4.6mm column (Phenomenex, Torrance, CA) using a gradient mobile phase of
methanol and 10mM ammonium formate, pH 2.75, at a flow rate of 0.4mL/min.
Detection was performed with an API 3000 triple-quadruple mass spectrometer (ABISciex, Foster City, CA) with electrospray ionization in multiple reaction monitoring
mode using the compound-specific mass transfers of m/z 453.3/247.3 for Lee 1329, m/z
459.2/207.2 for Lee 1443, m/z 471.3/207.1 for Lee 1445, m/z 487.2/128.3 for Lee 1544,
m/z 487.2/207.1 for Lee 1599 and m/z 418.3/207.1 for Lee 1369.
A calibration curve (range: 1.95 to 5,000μg/L) was constructed for each test
compound and validated with spiked samples of rat plasma or urine. The peak area ratios
of analyte to internal standard were linear over the concentration range tested for all
compounds, with all correlation coefficients (weighted least-square linear regression
analyses) >0.997. Accuracy (deviation of the analyzed quality-control samples from
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nominal values) was within ±3% over the entire range of the calibration curve, and the
precision (coefficient of variation of repeated measurements of the quality-control
samples) was <2% for all compounds.
Biodistribution
Radiolabeling of Lee 1329 (3’-Dihydro-3’-deoxy-3’(R)-(pyridin-2yl) acetylamino
spectinomycin Trihydrobromide) compound was performed by Dr.Richard E. Lee’s
group at St. Jude Children’s Research Hospital. The biodistribution study was conducted
in Sprague-Dawley rats (N=7, one control and 6 in the treatment group). The rats were
administered 3H-1329 intravenously (IV) via a femoral vein catheter at a dose of
0.9mg/kg body weight (0.87mCi/kg) every 12h for 4.5days. The control rat received
normal saline only. Serial blood samples were collected at 0 (pre-dose), 0.25, 2, 8 and
12h after the 1st dose and at 0 (before 8th dose), 0.25, 0.5, 1, 2, 4, 6, and 12h after the 8th
dose to evaluate the pharmacokinetics after single and multiple dosing. Plasma was
separated immediately after sample collection by centrifugation (10,000g for 10min at
4oC) and stored at -80oC until analysis of radioactivity by scintillation counting. Urine
and feces specimens were collected at 0h (pre-dose) and every 12h after dosing up to the
end of the study and stored at -80oC until analysis. The volume of urine and weight of
feces were noted at every sampling point for the calculation of mass balance. One hour
after the administration of the 9th dose, the animals were euthanized and all major organs
such as liver, kidneys, spleen, lung, heart, brain, thigh muscle and blood were collected to
determine tissue distribution and accumulation. Total blood was collected by cardiac
puncture. Major organs and tissues were collected and stored at -80oC until analysis.
Total volume of blood, urine, total weight of the organs, muscle and feces was noted for
the calculation of mass balance.
Sample preparation of biological samples for 3H-1329
Blood
0.2mL of blood was added to 1mL of Solvable™ (aqueous based solubilizer,
PerkinElmer, Waltham, MA) in a glass scintillation vial and incubated at 60oC for 1h.
0.1mL of 0.1 M EDTA-di-sodium solution was added to reduce foaming due to H2O2.
0.5mL of 30% H2O2 was added in 0.1mL increments and gently agitated after each
addition to allow reaction and foaming to subside. H2O2 treatment helps to reduce the
amount of color present, and thus reduces color quench in the final mixture. The mixture
was allowed to stand for 30min at room temperature to complete the reaction and was
incubated in a water bath at 60oC for 1h, venting any slight pressure occasionally. The
sample was then cooled to room temperature and 15mL of liquid scintillation cocktail
Ultima Gold™ (Perkin Elmer, Waltham, MA) was added. The samples were light
adapted for one hour before counting the radioactivity using a scintillation counter.

26

Serum and urine
The direct addition method was acquired to determine the amount of radioactivity
in serum and urine. 1.5mL of ethanol and 15mL of liquid scintillation cocktail Ultima
Gold™ was added in a glass scintillation vial to 0.1mL of serum or 0.5mL of urine and
shake well. The samples were light adapted for at least one hour before scintillation
counting.
Organs and muscle tissue
Organs (liver, kidney, spleen, lung, heart and brain) and muscle samples were
prepared by the solubilization method for the determination of accumulated radioactivity.
50mg of organs or muscle tissue was weighed into a scintillation vial and 2mL of
Solvable™ was added and heated on a water bath at 60oC for 1 to 3.5h with occasional
swirling. After cooling to room temperature, 0.2mL of 30% H2O2 was added slowly with
swirling between additions, and the mixture was allowed to subside any reaction between
additions of the H2O2. The mixture was heated again at 60oC for 30min for complete
decolorization. 10mL of liquid scintillation cocktail Ultima Gold™ was added, and the
samples were light adapted for at least one hour before scintillation counting.
Feces
The amount of radioactivity excreted in feces was determined by sample
combustion with a sample oxidizer (PerkinElmer Model 307 Sample Oxidizer, Waltham,
MA) and the recovered 3H was analyzed by scintillation counting. Briefly, feces
specimens of each animal collected at different time intervals were combined together
and homogenized with 4 volumes of water. Triplicate samples from each animal of
approximately 300mg of homogenate were placed in the sample oxidizer and combusted
in an oxygen rich atmosphere to oxidize the tritium present in the samples to water
(3H2O). The water was separated into a scintillation vial and mixed with 10mL of
scintillation cocktail Monophase-S (PerkinElmer, Waltham, MA). The samples were light
adapted for at least one hour before scintillation counting.
Sample analysis of biological samples for 3H-1329
The blood, serum, urine, organs, muscle and feces samples mixed with liquid
scintillation cocktail as described above were placed in a Tri-carb 2800 TR liquid
scintillation analyzer (PerkinElmer, Waltham, MA) to determine the tritium activity (3H).
The radioactivity was measured in terms of disintegrations per minute (DPM) setting the
energy window from channel 0 to channel 20. The luminescence from the sample was
reduced by setting a 10min pre-count delay. Samples were counted in the luminescence
correction mode. The average counting efficiency for 3H is 65.45%. The counting time
for each sample was 1min and each sample was analyzed three times. The quench
indicator tSIE (transformed spectral index of the external standard) was used as an
indicator of a good spectrum.
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Results and Discussion
Biopharmaceutical properties of spectinamides
As shown in Table 3-1, the molecular weight of spectinamides ranged from
between 450 to 600Da and is larger as compared to the spectinomycin with weighs
around 332.3Da. All of the spectinamides are highly hydrophilic in nature with clogP
between -3 and 0.
Plasma protein binding is an essential parameter in determining the drug
distribution, metabolism and elimination. A drug molecule that is circulating in the
system exists in two variants, protein bound and unbound (free), assuming that the
protein binding is reversible. The unbound and the bound form exist in equilibrium. The
unbound (free) drug is the only pharmacologically active drug as it can permeate the cell
membranes and exert the pharmacological effect on binding to target structure. Thus, it is
important to estimate the extent of plasma protein binding [43, 83, 84].
In general, spectinamides showed low to intermediate plasma protein binding in
rats. The only exception was Lee 1601 with 75% protein binding which can be attributed
to its increased molecular weight (563Da) as compared to the other lead compounds in
this series. The low plasma protein binding suggests that a large fraction of molecules is
freely available to enter the intracellular space for eliciting their therapeutic effect.
Lee 1544, Lee 1599, Lee 1601, Lee 1603, Lee 1661 and Lee 1666 are 2heteroaryl acetic acid amide analogs of spectinomycin that showed potent in vitro activity
against M. tb. The pharmacokinetic parameters for all these compounds are shown in
Table 3-1. Following intravenous administration of 10mg/kg in rats, all molecules
exhibited bi-exponential concentration time profiles with distinct distribution and
elimination phase (Figures 3-2 to 3-8) except Lee 1601.
All the lead candidate compounds in the spectinamide series showed comparable
alpha half-life of 0.58 to 1.06h, except for Lee 1601 with a very low alpha half-life of
0.28h. The compounds showed prolonged beta half-life, except Lee 1601. This prolonged
beta phase did not significantly contribute to the overall systemic exposure (AUC)
because of 100 to 1000 fold lower plasma concentrations than Cmax. This trend is
commonly seen in aminoglycosides and other amines and is associated with slow release
of the trapped molecules from deep tissue compartments. This phenomenon may be
attributed to lysosomal trapping and/or complexation with membrane phospholipids [8589].
The compounds showed a steady state volume of distribution in the range of 0.8
to 1.48L/kg except for Lee 1601 and Lee 1661 with Vd of 0.17 and 0.4L/kg, respectively.
The AUC ranged from 8.3 to 19.3h.mg/L. The AUC for Lee 1599 was slightly lower than
other spectinamide compounds. The MRT ranged from 0.2 to 1.84h and the mean
systemic clearance ranged from 0.5 to 1.22L/h/kg. The percent dose excreted unchanged
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Table 3-1.
Physico-chemical properties and pharmacokinetic parameters for spectinamides after intravenous
administration at 10mg/kg dose.
Name of the
compound
Lee 1544
Lee 1599
Lee 1601
Lee 1603
Lee 1661
Lee 1666
Spectinomycin

MW
(Da)

cLogP

PB
(%)

Cmax
mg/L

486.9 -2.51
486.9 -2.51
563.0 -0.697
550.6 -2.30
504.9 -2.34
500.9 -2.01
332.3 -2.87

15.0
13.0
75.0
55.0
40.0
42.0
13.0

12.1
9.94
15.9
16.2
23.4
15.2
20.6

t½
h

AUC
CL
h*mg/L L/h/kg

1.06
0.58
0.297
1.05
0.732
1.04
1.25

10.7
8.37
12.7
13.7
19.3
13.6
16.8

0.935
1.22
0.828
0.748
0.521
0.740
0.602

Vd
L/kg

MRT
h

Fe

0.868
0.820
0.167
1.41
0.358
1.48
0.756

0.931
0.680
0.197
1.84
0.687
1.98
0.757

0.520
0.885
0.129
0.283
0.860
0.74
0.553

Eratio % F
1.70
3.02
1.08
1.82
1.91
2.33
1.00

Notes: MW: Molecular Weight
cLogP: Calculate logarithm of partition coefficient
PB(%): Percentage protein binding
Cmax: Peak concentration in plasma
t1/2: Alpha half-life
Fe: Fraction excreted unchanged in the urine
Eratio: Excretion ratio
%F: Percent bioavailability is calculated using the AUC values obtained after oral administration at 100mg/kg
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4.00
3.47
0.377
2.03
1.75
-

Lee 1544
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Figure 3-2. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee 1544 in rats.
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Lee 1599
Concentration (μg/L)
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Figure 3-3. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee 1599 in rats.
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Lee 1601
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Figure 3-4. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee 1601 in rats.
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Lee 1603
Concentration (μg/L)

100000
10000
1000
IV

100

PO
10
1
0

12

24

36

48

Time (h)

Figure 3-5. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee 1603 in rats.
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Figure 3-6. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) and oral (100mg/Kg) administration of Lee 1661 in rats.
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Figure 3-7. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) administration of Lee 1666 in rats.
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Figure 3-8. Measured plasma concentration-time profiles (mean ± SEM) after
intravenous (10mg/Kg) administration of spectinomycin in rats.

36

in the urine (fe) ranged from 13% to 89%. Except for Lee 1601 and Lee 1603, all the
compounds had a high fe value 0.5, suggesting that the urinary excretion is the major
route of elimination for these compounds. The Eratio >1 for all the compounds suggests
active secretion as the net urinary elimination process.
Following 100mg/kg oral administration in rats, all compounds showed similar
bi-exponential concentration-time profiles (Figures 3-2 to 3-6) except for Lee 1601.
However, all tested spectinamides had poor oral bioavailability (F) ranging from 0.4 to
4%. Due to higher hydrophilicity, these molecules have limited membrane permeability
that likely leads to the poor oral bioavailability. One of the strategies to improve oral
bioavailability is by increasing the lipophilicity and reducing the polar surface area
without compensating the solubility of these molecules. Alternative route of
administration such as intrapulmonary route can also be assessed to determine an
improvement in the bioavailability [90-93].
Macrophage uptake assay
It has been commonly observed that macrophage ingest the M. tb as a defense
mechanism. After being ingested, M. tb continue to survive and multiply within
macrophages. Hence, it is important that the antimycobacterial agents reach the
intracellular region where bacteria thrive within macrophage [94-97]. The macrophage
uptake of spectinamides was evaluated by incubating the spectinamide agents with
macrophages and quantifying the intracellular uptake of the agents by macrophages.
Spectinomycin and streptomycin were used as controls for macrophage uptake.
Spectinamides are chemically derived from spectinomycin and streptomycin is an
aminoglycoside and also a second line agent to treat tuberculosis. The concentration of
drug uptake by macrophages after 24h incubation are shown in Table 3-2 and Figure
3-9. Lee 1329 and Lee 1599 showed significant penetration into macrophages as
compared to spectinomycin and streptomycin. As shown in Figure 3-10, Lee 1329 has a
6-fold and Lee 1599 has 5-fold higher uptake into macrophages as compared to
streptomycin. 1329 also has 2.2 fold higher uptake than spectinomycin. The results
indicate that spectinamides have substantial intracellular penetration into macrophages.
Biodistribution
Biodistribution studies with radiolabeled compounds provide a foundation in the
assessment of drug disposition as they provide understandings into mass balance, tissue
distribution, drug accumulation, circulatory and excretory metabolites, clearance
mechanisms and pharmacokinetics. This information is crucial to identify potential
toxicity and safety concerns of novel drug candidates, but also provides basic information
on systemic exposure [6].
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Table 3-2.
Mean concentration of drug uptake into J774A.1 murine macrophage
cell line at 24h for two different doses.

Compounds
Lee 1329
Lee 1443
Lee 1445
Lee 1544
Lee 1599
SP
ST

25μg/mL
ng/μg protein
1.17
0.44
0.762
0.413
1.04
0.599
0.184

SEM
0.287
0.205
0.125
0.026
0.032
0.099
0.017
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100μg/mL
ng/μg protein
SEM
0.753
4.04
0.187
0.624
0.411
2.71
1.37
0.036
3.31
0.055
0.503
1.86
0.68
0.052

Figure 3-9. Mean average concentrations (± SEM) of drug uptake into J774A.1
murine macrophage cell line at 24h.
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Figure 3-10. Fold differences in drug uptake in J774A.1 murine macrophage cell
line.
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Mass balance
The scintillation assay results revealed that 86.6% of administered radioactivity
was recovered in urine, feces, blood, muscle and organs throughout the length of the
study that included 9 doses of 0.9mg/kg 3H-Lee 1329 administered intravenously every
12h. It is challenging to achieve 100% recovery in mass balance studies due to several
practical limitations influenced by methodological, analytical or biological factors and
the quantitative investigation were not performed on all organs and tissues at the
termination of the study. These results, as shown in Figure 3-11, are in accordance with
other mass balance studies [98-100]. The samples were collected post 1h after the 9th
dose for mass balance determination. Approximately 70% of administered 3H-Lee 1329
was recovered in urine, 12.6% in feces and only 4% from all major organs, muscle tissue
and whole blood. The residual amount of 13.4% can likely be found in the animal
carcasses. Urine samples collected every 12h showed similar amount of radioactivity in
the range of 119.3 to 138.9μCi as shown in Figure 3-12. These results indicate that there
is no considerable accumulation of drug in the body during multiple dose administration.
Tissue distribution
The tissue distribution, penetration and accumulation of 3H-Lee 1329 and its
labeled metabolite was determined by analyzing the distribution of radioactivity to major
organs and muscles post 1h after administering the 9th dose. The observed data for
relative and absolute radioactivity for each major organ and tissue are presented in Table
3-3. The degree of tissue penetration was identified by measuring the fold differences in
amount of radioactivity per mg of tissue as compared to whole blood Figure 3-13. The
amount of radioactivity in lungs and spleen was 2.79 and 3.06 fold higher as compared to
whole blood. This infers that 3H-Lee 1329 possesses good tissue penetration into major
organs which are the primary site of infections by M. tb. Moreover, the amount of
radioactivity was less than one fold in other organs such as heart and brain.
Pharmacokinetic profile of radioactivity in serum
The concentration-time profiles for 3H-Lee 1329 after administration of 1st dose
and 8th dose are compared in Figure 3-14. The profiles are comparable for both the
doses for the first two hours with identical Cmax values. However, the concentrations of
radioactivity was 50% greater after the 8th dose as compared to the 1st dose. This
differences in concentrations at later time points indicates the possibility of metabolite
formation circulating with longer half-life than the parent drug.
Conversely, the systemic exposure (AUC0-τ) of radioactivity after the 1st dose and
8th dose were found to be very similar because of two reasons (i) The concentrations of
3
H-Lee 1329 2h post dose was very low compared to the Cmax and (ii) these
concentrations added only 21% of the total exposure (AUC0-τ) (Table 3-4). A comparison
of the systemic exposure characterized by Cmax and AUC0-τ following the 1st dose and
8th dose indicated an accumulation ratio R of 1.1, providing further evidence for the
absence of any substantial drug accumulation. R is a parameter used to quantify the
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Amount of 3H
excreted in Urine
69.965%
Residual
15.313%

Feces
12.619%
Whole Blood
0.017%
Muscle
0.016%

Spleen
0.049%

Brain
0.011%

Heart
0.015%

Liver
0.795%
Lung
0.056%

Kidney
1.144%

Figure 3-11. Mass balance and percentage distribution of Lee 1329-T at 1h post 9th
dose of 0.9mg/kg.
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Figure 3-12. Amount of radioactivity (mean ± SD) excreted in urine after each
dosing interval (0.9mg/kg 3H-1329, BID for 4.5days).
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Table 3-3.
Tissue distribution and recovery of radioactivity (mean(%CV))
following IV administration of 3H-1329 at 0.9mg/kg BID for 4.5days in rats.
Sample/Organ

Relative amount
of radioactivity
[μCi/g tissue]

Total amount
of radioactivity
[μCi]

% of
radioactivity
recovered

ADMINISTRATION
Total amount
administered

1432 (3.44)

RECOVERY
Blood

0.24 (12.2)

3.47

Liver

1.19 (13.7)

11.4

0.796 (5.99)

Kidney

7.92 (8.98)

16.4

1.15 (10.9)

Lung

0.64 (9.35)

0.805

0.056 (12.1)

Spleen

0.69 (11.5)

0.658

0.046 (13.8)

Heart

0.22 (9.32)

0.219

0.015 (24.9)

Brain

0.10 (18.1)

0.160

0.011 (39.6)

Muscle

0.23 (21.8)

24.7

0.242 (26.8)

1.72 (34.9)

Urine

17.90 (21.2)

1003

70.0 (2.99)

Feces

5.91 (39.6)

181

12.6 (29.8)

1242

86.6 (5.09)

Total amount
recovered
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Figure 3-13. Fold difference (mean ± SD) in tissue distribution of radioactivity
compared to amount in whole blood (after normalizing the distributions to μCi/mL
or μCi/mg of blood or tissue).
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Figure 3-14. Comparison of single and multiple dose pharmacokinetics showing
average (±SD) serum concentration-time profiles of radioactivity after the 1st dose
and 8th dose during multiple dosing with 0.9mg/kg 3H-1329 given intravenously
every 12h.
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Table 3-4.
Serum pharmacokinetic parameters after the 1st and 8th intravenous
dose of 0.9mg/kg 3H-1329 (values are expressed as mean (%CV)).
Parameter
tmax (h)
Cmax [mCi/L]
AUC0-W [mCi*h/L]

Dosing interval
1st
8th
0.25
0.25
3.39 (7.4)
3.55 (28.9)
5.08 (6.8)
5.17 (20.5)
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extent to which a compound will accumulate during multiple dosing relative to the first
dose and is calculated as ratio between AUC or Cmax during one dosing interval during
multiple dosing compared to the first dosing interval. An R value of 1 indicates absence
of any drug accumulation [101]
These results confirm that there is no substantial accumulation of 3H- Lee 1329 or
its metabolites. The recovery of 70% radioactivity in urine and 35-fold higher
concentration in kidneys compared to blood suggests that renal excretion is the major
route of elimination (or kidney is the major eliminating organ) for Lee 1329 and its
metabolites.
Conclusion
Select molecules from the spectinamide series were identified and characterized
via screening prototype involving various in vitro and in vivo assays. Spectinamides
demonstrated low to intermediate protein binding, shorter in vivo half-life at clinically
relevant concentrations and very low oral bioavailability. The compounds in the series
also expressed higher cellular uptake into macrophages as compared to streptomycin and
spectinomycin.
The biodistribution and mass balance study emphasized the favorable
pharmacokinetic properties of spectinamides as anti-TB agents; augmenting that
spectinamide Lee 1329 has excellent penetration into target tissues, did not accumulate in
tissue during multiple dosing, and forms low levels of circulating metabolites that are
excreted into urine and feces.
The pharmacokinetic parameters and tissue distribution data obtained in this
chapter provide the basis for the pharmacometrics-directed integrated PK/PD
characterizations in Chapters 4 and 5.
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CHAPTER 4. A PHARMACOMETRICS-BASED APPROACH USING IN
VITRO PK/PD MODELING TO DEVELOP DOSING REGIMENS FOR IN VIVO
STUDIES FOR A NOVEL SPECTINAMIDE ANTI-TUBERCULOSIS AGENT
Introduction
The increasing emergence of resistant mycobacterial strains in recent years and
the complications arising from treatment regimens are a strong reminder of the urgent
need for the development of new and more effective treatment options for tuberculosis
patients worldwide [67, 68, 72, 73]. Spectinamides, a novel class of spectinomycin
analogs, were designed to combate the increasing TB pandemic [81]. Spectinamides have
shown potent activity against mycobacteria in vitro and in vivo. Based on in vitro
screening assays and pharmacokinetic studies in rodents, Lee 1599 emerged as one of the
lead candidate molecules from the class of synthesized compounds. Lee 1599 has a
minimum inhibitory concentration (MIC) of 1.6μg/mL, and a favorable pharmacokinetic
profile with low (12.5%) protein binding, high microsomal metabolic stability, and renal
excretion as the primary elimination pathway. Although the half-life at effective
concentrations in rats was with 0.58h is relatively low, this property is counterbalanced
by a long post-antibiotic effect [81, 102, 103] that last approximately 133h when
mycobacteria were exposed to Lee 1599 at 10X the MIC.
The preliminary screening assays for new anti-infectives routinely include MIC
testing as one of the major pharmacodynamic measures of potency. Although the MIC
parameter is very informative at the early discovery phase, the limitations of this testing
method become evident as the in vitro knowledge about MIC can often not correlate very
well with in vivo efficacy in clinical settings. MIC is just a point estimate of
pharmacodynamic effect and does not describe the nature of bacterial killing over time
[39, 104, 105]. Thus, it is essential to have a more dynamic approach that has the ability
to translate the in vitro bacterial killing effect to in vivo conditions. Various in vitro
PK/PD modeling approaches have been utilized in recent years to capture the interaction
of fluctuating drug concentrations with bacterial killing over time. The benefits and
pitfalls of each method have been described elsewhere [10]. To obtain initial assessments
on PK/PD drivers of efficacy for new leads in drug discovery programs, a spinner-flask
based in vitro PK/PD model is a simple tool to generate time-kill curves for mycobacteria
under exposure to antibiotics. The fluctuating concentration-time profiles of the free,
pharmacologically active antibiotic as experienced during multiple dosing in vivo are
simulated in this approach using previously determined in vivo pharmacokinetic
parameters of the compound
In this article, we describe the dynamics of bacterial killing by Lee 1599 using an
in vitro PK/PD model. The Lee 1599 facilitated bacterial killing was characterized at
multiple dosing regimens by means of M. bovis BCG as model organism. An integrated
PK/PD model was generated based on the generated bacterial time-kill curves and the
simulated pharmacokinetic profiles of Lee 1599. Numerical simulations were
subsequently performed to predict the anti-mycobacterial activity of Lee 1599 for
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untested dosing regimens. This methodology has potential to guide researchers for
optimizing the dose selection process and study designs for further in vivo efficacy
testing.
Materials and Methods
Culture, media and antibiotics
M. bovis BCG was grown in Middlebrook 7H9 broth (Becton
Dickinson, Sparks, MD). The cultures were stored at -80°C in Middlebrook 7H9 broth.
For each experiment, cultures were thawed and incubated at 37°C in Middlebrook 7H9
broth until the bacteria reaches logarithmic phase (OD600 0.4-0.7). Lee 1599 (3’-Dihydro3’-deoxy-3’(R)- (5-chloropyridin-2-yl)acetylamino spectinomycin Trihydrobromide) was
synthesized and provided by our collaborators at St.Jude Children’s Research Hospital. A
solution of Lee 1599 was freshly prepared in sterile water before the start of each
experiment.
In vitro PK/PD model
As previously reported [39], the in vitro PK/PD model system consisted of a twoarmed, water jacketed flask (1965 series spinner flask, Bellco Glass, Vineland, NJ) as
depicted in Figure 4-1 [71]. A filter unit attached to a hollow steel tube is introduced into
the system. The filter unit contains a prefilter (5μm, Millipore, Billerica, MA) and filter
membrane (0.22μm, Millipore, Billerica, MA) to prevent leakage of bacteria during the
dilution process. The other end of the tube is connected to plastic tubing (PharMed
tubing, Cole-Parmer, Vernon Hills, IL) from which the media is withdrawn continously
at a defined flow rate using a peristaltic pump (Masterflex L/S, Cole-Parmer, Vernon
Hills, IL). The flask is placed on a magnetic stirrer for homogeneity of the culture and
preventing membrane blockage. The temperature of the system is maintained at 37oC
with the help of thermostatic water bath attached to the water-jacketed flask. One arm of
the flask in connected by plastic tubing to the fresh sterile media reservoir and the other
arm is used for dosing and repeated sampling. The solution of Lee 1599 is added through
the sidearm. The concentration of Lee 1599 in flask decreases exponentially as per the
equation:
 ܥൌ ܥ ି כ୩୲כ
C0 is the initial concentration of Lee 1599 in the flask following administration, C
is the concentration of Lee 1599 at any given time t, k is the elimination rate constant.
݇ൌ
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Figure 4-1.

A representation of working unit of an in vitro PK/PD model.
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where CL is the clearance of 1599, Vd is the Volume of distribution of 1599, F is the
flow rate of the media depicting Clearance, Vm is the volume of media in the flask, and
t1/2 is the half-life of 1599. All the above mentioned PK parameters were from obtained
by performing PK study in rats. The in vitro set up is assembled in a biosafety cabinet in
a sterile environment. The flask and the tubes are cleaned and sterilized by autoclaving
before starting every experiment.
Time kill curves for Lee 1599
M. bovis BCG was used as a test organism for evaluating the effect of Lee 1599 in
vitro model. The organism was grown to early logarithmic phase (O.D600. 0.4-0.7) in
Middlebrook 7H9 medium. This actively growing bacteria was used as an inoculum for
the in vitro model making the final density in the culture as 106 CFU/mL.
In separate experiments, different dose levels and dosing intervals of Lee 1599
were tested. The dosing regimens tested were 1mg QD, 5mg QD and BID, 10mg QD and
BID, 20mg QD, 25mg QD and BID, 50mg QD and BID and 100mg QD. Samples with an
approximate volume of 200μL were collected from the flask every 12h. The samples
were centrifuged at 10,000 rpm for 10min at 37oC. The pellets were collected and resuspended in an antibiotic-free medium. This step ensured that there was no drug carry
over effect. The samples were serially diluted and the dilutions were plated on 7H11 agar
plates in duplicates. The agar plates were incubated for 21days at 37oC. The effect of Lee
1599 was characterized by measuring the reduction in the number of viable bacteria, in
terms of CFU/mL. There was a control arm included in the study to determine the
bacterial growth in absence of drug.
PK/PD model building
The chemostat flask in the in vitro system resembled the central compartment and
total amount of drug administered in the central compartment. The concentration-time
profiles of the drug in the in vitro PK/PD model system were described with a simple
one-compartment model with first-order elimination:
 ܥൌ ܥ ି כ୩୲כ
where C is the concentration of Lee 1599 at any given time t, C0 is the
concentration of Lee 1599 at time 0h, k is the elimination rate constant.
The rate of change in the number of bacteria in the presence of drug was modeled using
the full PK/PD model as shown in Figure 4-2. The bacterial submodel and the PK model
were combined and the parameters are combined to characterize the effect of antibiotic
Lee 1599 on M. bovis BCG [105, 106] as shown in the equation below.
ܰ
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Figure 4-2. Schematic representation of PK/PD model to describe the rate of
change in the number of bacteria in the in vitro PK/PD model system.
Notes: C: Concentration of drug in central compartment
F: Bioavailability
ke: Elimination rate constant
ko: Growth rate constant
Ns: Total number of susceptible bacteria in the system
α: Delay rate constant
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The parameters in the equation are as follows: N is the number of viable bacteria
in the system, k0 is the bacterial growth rate constant, Nmax is the maximum number of
bacteria grown in the system in the absence of antibiotic, α is the delay rate constant for
growth, Imax is the maximum kill rate of the bacteria, C is the concentration of the drug
in the system at a given time point, IC50 is the inhibitory concentration at half maximal
kill rate. The logistic growth function added to the equation implies that the entry into the
stationary phase is attributed to self-limiting growth of bacteria. The delay rate constant
in incorporated to take into account the time taken by the drug to reach the site of action
in bacteria.
The time kill curves were analyzed using non-linear mixed effects modeling
(NONMEM v.7.2, ICON plc). The pharmacokinetic parameters were fixed in the
described PK/PD model to the following values: V=55mL, volume of media in the
system; half-life t1/2 = 0.58h. The first order conditional estimate method within
NONMEM was used to analyze the experimental time-kill curves. The between
experimental variability was modeled as proportional error. The model was evaluated
using various goodness of fit plots.
The appropriate PK/PD index associated with the bacterial kill by Lee 1599 was
determined by calculating the individual indices and subsequently fitting an inhibitory
Emax model to the colony count at a specific time point versus PKPD index data using
nonlinear regression:
ܧ௫ ܦܲܭܲ כௗ௫
 ܧൌ ܧ െ ൬
൰
ܥܧହ  ܲܦܲܭௗ௫
where, E is the observed M. bovis BCG counts in Log CFU/mL, E0 is the bacterial count
in the control experiment, Emax is the maximum anti-bacterial effect in Log CFU/mL and
EC50 is the value of PK/PD index that produces half-maximal antibacterial effect.
PKPDindex is one of three empirical PK/PD indices frequently used for antibiotics
pharmacotherapy such as AUC0-24/MIC, Cmax/MIC or T>MIC. The most appropriate
PK/PD index that best described the bacterial killing was selected based on visual
inspection and goodness of fit criteria.
Numerical simulations
Numerical simulations were performed using the developed PK/PD model and the
parameter estimates derived from the time kill experiments to predict the effect of
different untested doses and dosing regimens in a murine in vivo infection model of
mycobacteria. The PK parameters of Lee 1599 in mouse were obtained from a mouse
bridging studies as published elsewhere[81]. Dosing regimens ranging from 1mg/kg to
200mg/kg with QD, BID and TID dosing were simulated using the in vivo PK parameters
and PK/PD estimates obtained from experimental time kill curves. 1000 datasets were
simulated for each dose/dosing regimen using NONMEM 7.2
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Results
Time kill curves for Lee 1599
The bacillary load in tuberculosis patients varies from 6-9 log CFU/mL in cavity
walls [107]. Thus, the experiment was initiated with a bacterial burden of approximately
6 log CFU/mL and 7 log CFU/mL. The time kill experiments were carried out for Lee
1599 against M. bovis BCG with various dose and dosing regimens as shown in Figure
4-3 (N0: 6-7 log CFU/mL) and Figure 4-4 (N0: 7-8 log CFU/mL). The samples were
collected every 12h up to 96h (Day 4) for all the studies. All the studies were performed
in duplicate (N=2). LC-MS analysis has demonstrated that Lee 1599 is stable in 7H9
media for up to 144h. The untreated control group showed a 2-log increase in bacterial
growth through the length of the study. The lowest treatment dose of 1mg/kg QD dosing
did not show any change in bacterial counts, indicating similar doubling time and death
rate. At 5mg/kg QD and 10mg/kg QD, Lee 1599 showed a bactericidal effect and a
decrease in bacterial count was observed. However, Lee 1599 did not show a significant
difference (p>0.05) in bacterial counts at a very high dose of 100mg/kg QD compared to
50mg/kg QD (p=0.0729 at 48h and p=0.278 at 72h). The antibiotic effect improved
substantially with BID and TID dosing as compared to QD dosing using the same daily
dose. An increase in bacterial killing was observed with 5mg/kg BID (10mg/kg/day) and
3.33mg/kg TID (10mg/kg/day) as compared to 10mg/kg QD dosing. Similarly, 50mg/kg
BID (100mg/kg/day) dosing was more effective than 100mg/kg QD.
The time kill curves for M. bovis BCG were described using a semi-mechanistic
PK/PD model. The effect of Lee 1599 on bacteria was characterized by incorporating an
inhibitory sigmoidal Emax model with delay rate constants that reduced the growth rate
in a concentration-dependent fashion. The growth rate constant was estimated to be
0.0368h-1 that equals to a doubling time of 18.83h. The doubling time is in accordance
with the values reported in the literature [108, 109] indicating that the growth rate was
not affected by the in vitro PK/PD model system. A maximum bacterial kill rate (Imax)
was calculated as 0.0355h-1, suggesting that it takes nearly 19.5h for the bacterial counts
to be halved. The concentration of the drug required to produce half-maximum inhibition
(IC50) was calculated as 0.0437mg/mL. A delay rate constant was introduced in the
equation to explain the delay in the initiation of the actual killing effect. The delay rate
constant was estimated to be around 0.0209h-1. The results of this analysis are shown in
Table 4-1 and the model diagnostics and predictions for various dosage regimens are
shown in Figures 4-5 and 4-6.
The PK/PD index for Lee 1599 was determined using a sigmoidal inhibitory
Emax model. The bacterial kill on Day 2, 3 and 4 (only Day 4 data shown) suggested that
Lee 1599 follows both AUC/MIC and Cmax/MIC as PK/PD index (Figure 4-7). Besides
visual inspections, various model diagnostics such as AIC, BIC and -2LL are used to
estimate the relative quality of statistical models and as a means of model selection.
These goodness-of-criteria also demonstrated that AUC/MIC and Cmax/MIC are
appropriate PK/PD indices as compared to T>MIC (Table 4-2). AUC/MIC index
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Figure 4-3. Timekill effect of Lee 1599 against M. bovis BCG (N0: 6-7 log
CFU/mL) with observed log CFU/mL plotted against time for different dosing
regimens.
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Figure 4-4. Timekill effect of Lee 1599 against M. bovis BCG (N0: 7-8 log
CFU/mL) with observed log CFU/mL plotted against time for different dosing
regimens.
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Table 4-1.

In vitro PK/PD parameter estimates for Lee 1599.

Parameter

α (h-1)
Ko (h-1)
N (CFU/mL)
Nmax (CFU/mL)
Imax (h-1)
IC50 (mg/mL)

Estimate
(%RSE)

Between
experimental
variability
(%RSE)
0.754 (38%)
0.124 (106%)
0.00304 (85%)
0.00483 (57%)

0.0209 (49%)
0.0368 (40%)
6.82 (2%)
8.27 (4%)
0.0355 (27%)
0.0437 (61%)

Notes: RSE: Residual Standard Error
α: Delay rate constant
Ko: Growth rate constant
N: Initial number of bacteria
Nmax: Maximum number of bacteria
Imax: Maximum bacterial kill rate
IC50: Concentration required to produce half-maximal effect
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Residual error
(%RSE)
0.00591 (32%)

(A.)

(B.)

(C.)

(D.)

Figure 4-5. Panels showing goodness of fit plots for the Lee 1599 PK/PD model fit
(A.) DV vs PRED (B.) DV vs IPRED (C.) PRED vs CWRES (D.) TIME vs CWRES.
Notes: (A.) Observed effect (DV) vs population prediction (PRED)
(B.) Observed effect (DV) vs individual prediction (IPRED)
(C.) Population prediction (PRED) vs conditional weighted residuals (CWRES)
(D.) Time vs conditional weighted residuals (CWRES)
CWRES is a model diagnostic for evaluating model misspecification. It is calculated
based on first order conditional estimate (FOCE).
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Figure 4-6. Plots showing measured (DV is observed data), individual predictions
IPRED (black lines) and population predictions (red lines) for M. bovis BCG
CFU/mL over time for the Lee 1599 PK/PD model.
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A.)

B.)

C.)

Figure 4-7.
treatment.

Relationship between PK/PD indices and microbial kill on Day 4 after

Notes: Panels A, B and C shows AUC/MIC, Cmax/MIC and T>MIC, respectively. The
red dots are observed data points and blue lines are model predicted lines.
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Table 4-2.

Empirical PK/PD indices based on day 4 data.

Parameter
EC50
Econtrol
Emax
AIC
BIC

AUC/MIC (%CV)
14.7 (71.03%)
10.2 (20.7%)
8.09 (24.09%)
48.3
50.4

Cmax/MIC (%CV)
3.63 (79.06%)
11.2 (28.4%)
8.97 (32.5%)
47.9
50.09

Notes: EC50: Effective concentration to achieve 50% of maximal effect
Econtrol: Initial M. bovis BCG counts in absence of drug (at time 0, pre-treatment)
Emax: Maximum effect achieved on Day 3
AIC: Akaike information criterion
BIC: Bayesian information criterion
%CV: % Coefficient of Variation
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T>MIC (%CV)
1.42 (211.8%)
12.2 (65.2%)
9.70 (68.6%)
56.4
58.5

suggests that Lee 1599 follow both concentration and time dependent killing as opposed
to time dependent killing pattern observed commonly with aminoglycosides. The
potential explanation for the difference in PK/PD index of Lee 1599 and other
aminoglycosides can be related to the lengthy post-antibiotic effect (PAE) of 133h for
Lee 1599 at 10X MIC. This can be achieved clinically by administering higher doses
more frequently so that higher concentration of drug stays above MIC for longer periods
in spite of clinically relevant shorter half-life for Lee 1599.
Numerical simulations
The pharmacokinetic parameters from a mice bridging study and
pharmacodynamic parameters from the in vitro time kill experiments were combined in a
PK/PD model as shown in Figure 4-8. Numerical simulations for time-kill curves were
performed utilizing parameters from this PK/PD model to predict the effect ascertained
by Lee 1599 at various untested dosing regimens in mice. The simulated profiles for QD,
BID and TID dosing regimens are shown in Figure 4-9, 4-10 and 4-11 respectively. The
simulations also suggest that there is a dose dependent killing indicating an evident dose
response relationship. The efficacy was higher with increasing doses for all the three
regimes, however, for TID dosing regimen, there was a ceiling effect observed at very
high doses of 50mg, 100mg and 200mg TID. Although the total daily doses were the
same, BID and TID dosing showed better efficacy as compared to QD dosing regimens.
Discussion
The urge to combat tuberculosis is constantly on the rise and numerous research
groups have discovered new drugs and tested globally. The preliminary screening of
these drugs during the early discovery program are often based on target inhibition
studies and MIC testing. The monitoring of the dynamic interplay between the drug and
bacteria becomes more relevant as the concentration of drug changes over time in vivo as
opposed to the static time kill studies of MIC testing where the concentration of drug
remains constant throughout the course of the study. Several research groups have
performed static time kill studies using bacteria that have very fast doubling time [110].
Since, M. tb have a lengthy doubling time, it might be even more misleading to perform a
time kill study under static conditions. Hence, the need for dynamic in vitro PK/PD
models are evident. The utility of dynamic models such as the applied in vitro PK/PD
model is primarily to identify the nature and time course of the anti-bacterial effect
obtained from the antibiotic in question and to apply these findings to extrapolate the PD
effect to the in vivo situation.
The time kill curves for Lee 1599 showed dose-dependent killing with the tested
dosing regimens. The estimates obtained from semi-mechanistic PK/PD model were used
for numerical simulations of the kill dynamics of varying dosing regimen in a mouse
model of tuberculosis infection under the assumption of an absence of the animal’s
immune response. For this purpose, PK parameter estimates were used from a mouse
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Figure 4-8.

Schematic representation of PK/PD model used for simulations.

Notes: * indicates that the bioavailability of 1 was assumed for modeling and simulation
purposes. SC is subcutaneous route of administration, C is the central compartment and P
is the peripheral compartment. The pharmacokinetic parameter estimates were obtained
from PK studies performed in mice.

64

8

Log CFU/mL

6

4

2
0

24

48

72

96

120

144

168

Time (h)
Control
1mg QD
5mg QD
10mg QD
50mg QD
100mg QD
200mg QD

Figure 4-9. Time kill curves calculated from 1000 numerical simulations for once
daily dosing regimen of Lee 1599 in mice.
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Figure 4-10. Time kill curves calculated from 1000 numerical simulations for twice
daily dosing regimen of Lee 1599 in mice.
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Figure 4-11. Time kill curves calculated from 1000 numerical simulations for
thrice daily dosing regimen of Lee 1599 in mice.
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bridging studies previously performed by our group. The simulations using mouse PK
parameters suggested that Lee 1599 elicits exposure (concentration and time) dependent
killing as opposed to only dose dependent killing. For QD dosing regimens, the
simulations indicate regrowth in the bacterial counts once the drug is cleared from the
system. This can be possible due to short half-life of the Lee 1599 at clinically relevant
concentrations. The regrowth could not be captured in vitro model system because of the
limited number of sampling time points. The compound still causes a significant bacterial
reduction with QD regimen at higher doses. With BID and TID regimen, a similar effect
in efficacy is observed for higher doses 50mg, 100mg and 200mg. At such high doses,
there is a dramatic reduction in bacterial counts reaching sterilization. However,
prolonged administration at such high doses is not necessary as similar efficacy can be
achieved at a dose lower than 50mg BID.
We also performed simulation exercises with the dosing regimens used for the in
vivo efficacy trials by our collaborator Dr.Lenaert’s and her group at Colorado (5 days a
week with 2 consecutive drug holidays) in order to visualize the effect of dosing holidays
with regards to efficacy of Lee 1599 in mice. The simulations are shown for QD and BID
dosing in Figure 4-12 and 4-13. These simulations are stochastic simulations taking into
account the drug holidays and prediction intervals. The simulated effect was the bacterial
log reduction in the central compartment. There is a regrowth of bacteria observed during
the holiday period. With QD dosing, only 200mg/kg showed a significant effect as
compared to other dose groups. There was no efficacy observed at doses up to 40mg/kg.
In BID dose groups, there was a substantial decrease in bacterial counts at doses above
20mg/kg BID (i.e. 40mg/kg/day). This suggests that higher doses with shorter dosing
intervals are desirable for accomplishing an optimal antibacterial effect for Lee 1599. The
simulations of the in vivo efficacy trials also helped us in understanding the relevant
PK/PD index. It clearly suggests that, both, higher exposure of drug and shorter dosing
intervals are required to achieve optimal effect. This finding correlates well with the
identified relevant PK/PD index of AUC/MIC.
However, the simulations based on the in vitro PK/PD model may not be
extrapolated precisely and quantitatively to predict the in vivo conditions due to several
factors. The PK/PD model established from the in vitro PK/PD model provides
information about direct interaction of drug with bacteria in the absence of the immune
system. Also, 100% of drug is available at the site of action i.e. the bacteria in the central
compartment of the in vitro PK/PD model without any barrier for drug distribution such
as biomembranes. In contrast, in the in vivo situation, the bacteria reside in the lungs and
localized within the alveolar cellular compartment (and spleen) as well as within
macrophages and the drug has to permeate into the lung tissues to cause the desired
effect. The results might be more accurate if we obtain further information such as
biodistribution in lung tissues and subcellular compartment with respect to plasma.
In addition, the drug is administered subcutaneously in the in vivo efficacy trials
in mice and the bioavailability of Lee 1599 is unknown for this route of administration in
mouse. The model prediction assumes bioavailability of 100% reaching the lung tissues
for numerical simulations, which may not be the case. Also, different bacterial strains
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Figure 4-12. Time kill curves calculated from 1000 numerical simulations for once
daily (5 days a week) dosing regimen of Lee 1599 in mice.
Notes: The shaded region (grey zone) is the 90% confidence interval and the dark lines
are the mean bacterial counts in log CFU/mL.
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Figure 4-13. Time kill curves calculated from 1000 numerical simulations for twice
daily (5 days a week) dosing regimen of Lee 1599 in mice.
Notes: The shaded region (grey zone) is the 90% confidence interval and the dark lines
are the mean bacterial counts in log CFU/mL.
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were used for the in vivo studies (M. tb. Erdman) and the in vitro PK/PD model (M. bovis
BCG) which may affect the model based predictions of in vivo efficacy trials. The
doubling times and the logarithmic growth phase of bacteria can be effected under in
vitro and in vivo conditions. Despite these shortcomings, it is beneficial to perform
studies using an in vitro PK/PD model and execute pharmacometric analyses to gain
knowledge about the dose fractionation studies and identifying PK/PD indices. These in
vitro studies helped us in facilitating the decision making process during the transition to
in vivo studies. It aided us in selecting an appropriate dosing regimen for in vivo trials in
order to characterize an exposure-response relationship.
Conclusions
We successfully determined the time kill profiles for dosing regimens of Lee 1599
against M. bovis BCG. The semi-mechanistic PK/PD model was competent to describe
the effect of Lee 1599 on the growth and survival of bacteria. The simulations suggested
that higher doses are more effective than very low doses irrespective of the frequency of
dosing. The optimal effect in in vivo mouse models can likely be achieved with twicedaily dosing regimens. These findings support the rational of utilizing a PK/PD based in
vitro model system to characterize the dose response relationship of spectinamides and
obtain an understanding of the best PK/PD index as driver of efficacy and the effect of
dose fractionation studies to maximize efficacy for in vivo trials.
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CHAPTER 5. APPLICATION OF PHARMACOMETRIC TOOLS FOR
IDENTIFYING PHARMACODYNAMIC INTERACTIONS IN ANTIBIOTIC
COMBINATIONS
Introduction
The mechanism of action for spectinamides is similar to that of spectinomycininhibiting protein synthesis by selectively binding to the head domain of the 30S
ribosomal subunit and blocking its translocation [77]. Although there can be multiple
redundancies or alternate pathways in response to such inhibition by a single antibiotic,
most often this results in drug resistance or clinical relapse. For these reasons,
combination therapies are needed for more durable and effective treatment [111]
Combination therapy of new and existing anti-TB agents are constantly being evaluated
to determine the pharmacodynamic interaction between two agents. The selection of
combination compounds will aid in treating patients with MDR-TB and also shorten the
duration of treatment [112].
The primary objective of this research study was to find a combination partner
agent for lead spectinamide molecule Lee 1599. We selected rifampicin (RIF) as a model
compound for combination agent as rifampicin has been in use for TB therapy for several
decades. The elementary justification for combination therapy is expecting an enhanced
pharmacodynamic effect with two or more agents. The net effect of any
pharmacodynamic interaction can be synergistic, antagonistic or additive. The screening
for an efficacious partner agent for a new molecule is a critical step in the early discovery
phase before performing any extensive in vivo trials.
To determine the interaction between the two agents, we applied the widely
accepted checkerboard assay method as a primary screening tool. The checkerboard assay
can be used for qualitative interpretation only as it does not provide any information on
the degree of interaction between Lee 1599 and RIF. An alternative approach is to
quantitatively assess the interaction by utilizing a parametric method known as three
dimensional surface response assay. The basis for both these methodologies is set on
different principles [113-115]. Thus, the expected outcome for an interaction between
two drugs may or may not be similar from these methodologies. It is essential to identify
an appropriate screening tool for selection of candidate compounds as it helps in
accelerating the preclinical drug development process.
Herein, we illustrate the differences in outcomes of the checkerboard assay and
the response surface assay, which is instrumental in screening the potential combination
compounds that are urgently required to curb evolving resistant strains. The results of the
surface response assay were validated using an in vitro PK/PD model for combination
therapy by generating dynamic time kill curves at different dose levels and dosing
regimens. Further, we compared these results of the pharmacodynamic interaction
between Lee 1599 and RIF with in vivo studies in a mouse model of infection to further
validate our outcomes.
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Materials and Methods
Antimicrobial agents
The spectinamide Lee 1599 (3’-Dihydro-3’-deoxy-3’(R)- (5-chloropyridin-2-yl)
acetylamino spectinomycin Trihydrobromide) was synthesized in the laboratory of Dr.
Richard.E. Lee at St.Jude Children’s Research hospital. Rifampicin (RIF) was purchased
from Sigma (St. Louis, MO). A stock solution of each agent was prepared and stored at
4°C. Prior to each susceptibility testing, an aliquot of each agent was diluted to the
desired concentration with 7H9 media.
Microorganisms
M. bovis BCG was grown in Middlebrook 7H9 broth (Becton Dickinson, Sparks,
MD). The cultures were stored at -80°C in Middlebrook 7H9 broth. For each experiment,
cultures were thawed and incubated at 37°C in Middlebrook 7H9 broth until the bacteria
reaches logarithmic phase (OD600 0.4-0.7). M. tb Erdman (TMC 107, ATCC 35801) was
used as testing organism for animal studies.
Checkerboard assay
The pharmacodynamic interaction between Lee 1599 and RIF against M. bovis
BCG was evaluated using the checkerboard assay. The assay was carried out in 96-well
plate format with varying concentrations of Lee 1599 and RIF serially diluted in 7H9
media across rows and columns, respectively. The concentrations for Lee 1599 and RIF
ranged from 0.003 to 6.4μg/mL and 0.00049 to 2μg/mL, respectively, with a final
volume of 100μL in each well. Additionally, 100μL of M. bovis BCG culture with OD600
of 0.01 was also added to each well. The plate was incubated for 7 days at 37°C and the
endpoint assessment was based on visual growth inspection. The fractional inhibitory
concentration index (FICI) calculated for each concentration in each combination is
represented by the following equations:
 ൌ ͳͷͻͻ  
ܥܫܨଵହଽଽ ൌ

ܥܫܨோ ൌ

ܥܫܯଵହଽଽ ݅݊ܿ݊݅ݐܾܽ݊݅݉
ܥܫܯଵହଽଽ ݈ܽ݁݊
ܥܫܯோ ݅݊ܿ݊݅ݐܾܽ݊݅݉
ܥܫܯோ ݈ܽ݁݊

FICI represents the extent of interaction between two drugs in question and the
interaction can be defined as synergistic (FICI < 0.5), antagonistic (FICI > 4.0) or
additive (0.5 < FICI < 4.0).
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Response surface assay
Static time-kill studies were performed in a 5x5 array with different concentration
combinations for Lee 1599 and RIF. Five concentrations of each agent, 0 (Control), 0.05,
0.5, 1 and 2X MIC, were used. M. bovis BCG was grown to the logarithmic phase (OD600
0.4-0.7) in Middlebrook 7H9 medium. The logarithmically growing culture was then
used to initiate the time kill studies (starting OD600 0.15). The final concentration of
bacterial culture in each tube was approximately 108 CFU/mL. The culture was treated
with different antibiotic concentrations for 24h at 37°C on a shaker (200 rpm). Bacterial
samples were collected from each tube after 24h for quantification. Prior to
quantification, the samples were centrifuged at 37°C at 10,000 rpm for 10min and the
supernatant was discarded. This step is required to ensure that there is no antibiotic carry
over effect. The bacterial pellet was diluted with the same amount of fresh 7H9 media
and serially diluted with 7H9 media. The dilutions were plated on 7H11 agar plates for 21
days at 37°C and the colonies were counted manually on each plate post-incubation. The
anti-bacterial effect was determined as the decrease in number of viable bacteria in terms
of CFU/mL.
The antibacterial effect after 24h of treatment with drugs was described using an
inhibitory Emax model. The parameter estimates describing the killing effect were
estimated by nonlinear regression analysis using Phoenix WinNonlin 6.3 (Certara, NJ).
The total bacterial density for the treatment groups was then modeled with the obtained
parameters using three dimensional surfaces. Null interaction (or additivity) was used to
model the effect summation for combination treatment as follows:
ݐ݂݂ܿ݁ܧ௧௧ ൌ ݐ݂݂ܿ݁ܧଵହଽଽ  ݐ݂݂ܿ݁ܧோ
ܧ௫ǡோ ܥ כோ
ܧ௫ǡଵହଽଽ ܥ כଵହଽଽ
ܲ  ݀݁ݐܿ݅݀݁ݎȀ ൌ ܧ െ ቆ
ቇെቆ
ቇ
ܥܧହǡଵହଽଽ  ܥଵହଽଽ
ܥܧହǡோ  ܥோ
where E0 is the growth at 24h in the absence of antibiotics, Emax, Lee 1599 / Emax,Rif is the
maximal effect of Lee 1599/ RIF, EC50,Lee 1599 /EC50,RIF is the effective concentration of
Lee 1599/RIF to achieve 50% of maximal effect, CLee 1599/CRIF is the concentration of Lee
1599/RIF.
Volume under the plane (VUP) for both observed and predicted effect was
calculated using MATLAB 8.2. The interaction index (II) is the ratio of
VUPobserved/VUPpredicted and it defines the pharmacodynamic interaction between
two agents as synergism (II<1) and antagonism (II>1). An II around 1 suggests no
interaction, i.e. an additive effect.
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In vitro PK/PD model
The dynamic time kill curves for different doses of Lee 1599 and RIF were
established using a modified version of our in vitro PK/PD model. As described
previously, [39] the in vitro PK/PD model system consists of a two-armed, water jacketed
flask (1965 series spinner flask, Bellco Glass, Vineland, NJ) as depicted in Figure 4-1. A
filter unit attached to a hollow steel tube was introduced into the system. The filter unit
contained a prefilter (5μm, Millipore, Billerica, MA) and filter membrane (0.22μm,
Millipore, Billerica, MA) to prevent leakage of bacteria during the dilution process. The
other end of the tube was connected to plastic tubing (PharMed tubing, Cole-Parmer,
Vernon Hills, IL) from which the media was withdrawn continuously at a defined flow
rate using a peristaltic pump (Masterflex L/S, Cole-Parmer, Vernon Hills, IL). The flask
was placed on a magnetic stirrer for homogeneity of the culture and preventing
membrane blockage. The temperature of the system was set at 37oC with the help of a
thermostatic water bath attached to the water-jacketed flask. One arm of the flask was
connected by plastic tubing to the fresh sterile media reservoir and the other arm was
used for dosing and repeated sampling.
For simultaneously generating the concentration-time profiles for two antibiotics,
additional components were added to the model utilized for a single drug treatment. The
additional component is a supplementing compartment that contains the second
administered drug. As shown in Figure 5-1, one of the sidearm of the flask is connected
to the reservoir containing sterile medium and the supplementing compartment. The drug
having the higher clearance was administered as bolus dose from the side arm. The flow
rates (F) of the inlet and outlet in the central compartment and supplementing
compartment were computed based on equations described by Jürg Blaser [116]. The
individual values of each flow rate in and out of supplementing and central compartment
are shown in Figure 5-1. A supplementing reservoir contains media with the drug with
the slower clearance. The change in concentration per unit time will be same in both the
compartments. Thus, the volume of supplementing compartment and flow rate is
calculated as:
ܮܥ െ ܮܥ
൰ ܸ כ
ܸ௦ ൌ ൬
ܮܥ
ܨൌ

ܸ Ͳ כǤͻ͵
ݐଵȀଶ

Where, Vs is volume of media in the supplementing compartment; CLA and CLB
are the clearance of Drug A and B; Vc is volume of media in the supplementing
compartment (55mL); F is the flow rate of media and t1/2 of drug was obtained from in
vivo studies in rats. The t1/2 of Lee 1599 was experimentally determined and RIF was
obtained from literature [117].
The combination tested in this experiment was Lee 1599 and rifampicin. Lee
1599 (Drug A) has a higher clearance than rifampicin (Drug B). The in vitro set up is
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Figure 5-1.
studies.

A representation of in vitro PK/PD model set up for dynamic time-kill

Notes: Drug A is Lee 1599 and Drug B is RIF.
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assembled in a biosafety cabinet in a sterile environment. The flask and the tubes are
cleaned and sterilized by autoclaving before starting every experiment.

Time kill curves for Lee 1599
M. bovis BCG was used as a test organism for evaluating the effect of drug in
vitro model. The organism was grown to early logarithmic phase (O.D.600 0.4-0.7) in
Middlebrook 7H9 medium. This actively growing bacteria was used as an inoculum for
the in vitro model making the final density of the culture as 106 CFU/mL.
Samples of 200μL were collected every 12h from the central compartment flask
with volume replacement containing fresh media. The samples were centrifuged at
10,000 rpm for 10min at 37oC. The formed pellets were collected and re-suspended in
antibiotic-free media. This step was to ensure that there is no drug carry-over effect. The
samples were serially diluted and the dilutions were plated on 7H11 agar plates in
duplicate. To check if there are any resistant colonies forming bacteria, the samples were
also plated on agar plates with 1X, 2X and 4X MIC of each drug. The agar plates were
incubated for 21days at 37oC. The efficacy of Lee 1599 was characterized by measuring
the reduction in number of viable bacteria, in terms of CFU/mL. There was a control arm
included in the study to determine the bacterial growth in absence of drug.
In vivo efficacy studies
The results of the checkerboard assay, the response surface assay and the in vitro
PKPD model were compared to results of in vivo efficacy studies for Lee 1599 and RIF.
The methodology for the animal studies and the endpoint analysis are described as Model
2 and 3 in a previous study [81]. The formulation for Lee 1599 was freshly prepared
using 5 parts of USP Multiple Electrolytes Solution (PlasmaLyte, Baxter Healthcare
Corp., Deefield, IL) and 1 part sterile deionized water. RIF was ground to a fine powder
using mortar and pestle, and sterile deionized water was added incrementally to the total
volume. The formulation was stored at 4oC until required. Lee 1599 was administered
subcutaneously at 200mg/kg QD and RIF was administered orally at 10mg/kg QD. For
the combination studies, both drugs were administered simultaneously at the same doses
and route of administration as given in monotherapy.
Results
Checkerboard assay
The drug aliquots were stable at the beginning of experiments and this was
confirmed using LC-MS analysis. In the checkerboard assay, the positive control wells
that did not contain any drug showed bacterial growth at the end of the incubation period
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as expected. The MIC of Lee 1599 was found to be 0.8μg/mL, which is consistent with
the MIC determination that had been performed during the initial screening of the
spectinamide series. The MIC of Lee 1599 was found to be similar for M. bovis BCG and
M. tb. The FICI score for Lee 1599 was 0.375 as shown in Table 5-1. The MIC of both,
RIF and Lee 1599 was significantly reduced in the presence of each other. As the FICI
score for this tested combinations is below 0.5 it suggests that RIF has a synergistic
interaction with Lee 1599.

Response surface assay
Lee 1599 and RIF exhibited similar concentration-killing profiles in pilot studies
as shown in Figure 5-2. The optimal concentration was found to be approximately
6.4μg/mL for 1599 and 1.6μg/mL for RIF. There was no ceiling effect observed for both
of the drugs. A reasonable model fit was obtained for Lee 1599 (r2=0.992) and RIF
(r2=0.996) for the applied inhibitory sigmoid Emax-model based on model diagnostics.
The concentrations for capturing the most precise parameter estimates describing the
killing effect for Lee 1599 were found at 0.04, 0.4, 0.8, 1.6, 3.2 and 6.4μg/mL, whereas
the concentrations to obtain parameter estimates for RIF were 0.02, 0.2, 0.4, 0.8 and
1.6μg/mL.
To analyze the pharmacodynamics interaction between Lee 1599 and RIF, we
plotted the combined effect of both the agents using a three-dimensional response surface
approach (Figure 5-3). A three dimensional plot of bacterial count vs. concentration was
plotted with Lee 1599 concentration on the x-axis, RIF concentration on the y-axis and
bacterial count in Log CFU on the z-axis. The “null interaction” surface was constructed
in a separate plot using a set of points representing model predicted additive effect of
combinations of Lee 1599 and RIF and is shown in Figure 5-4. In all different sets of
concentrations of the compounds in combination, an increased killing effect was seen as
compared to either drug alone at the same concentration. The killing effect by one agent
was supplemented by the presence of the other agent. The volumes under the plane
(VUP) for the observed effect and model predicted effect as shown in Table 5-2 are
274.84 and 271.86 log CFU μg2/mL3. The interaction index calculated based on the
obtained VUPs was found to be 1.01 indicating an additive effect exerted by the
combination of Lee 1599 and RIF.
In vitro PK/PD model for combination agents
For the in vitro PK/PD model, three different dosing regimens for Lee 1599 and
two for RIF were selected to be investigated in combination experiments: 100mg/kg QD,
10mg/kg QD and 1mg/kg QD for Lee 1599 and 10mg/kg QD and 0.5mg/kg QD for RIF.
As shown in Figure 5-5, there was a marginal increase in the average bacterial killing
when both the agents were used in combination as compared to when administered
individually. The bacterial counts were below limit of quantification for the timepoints
without any data points beyond 48h or 72h in the time-kill curves. The bacterial counts at
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Table 5-1.
Checkerboard assay results to determine pharmacodynamic
interaction between Lee 1599 and RIF.
Agent

MIC of
agent alone
(μg/mL)

Rifampicin

0.002

MIC in
presence of
Lee 1599
(μg/mL)
0.0005

MIC of Lee
1599 in
presence of
agent (μg/mL)
0.1

Note: The MIC of Lee 1599 alone is 0.8μg/mL.
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FICI
score

Indication

0.375

Synergy

(A)
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൰
݃ܮଵ ܷܨܥȀ݉ ܮൌ ͻǤ͵ͳͳ െ ൬
ͳǤʹ  ܥଵହଽଽ

(B)

Ǥͳͷ ܥ כோூி
൰
݃ܮଵ ܷܨܥȀ݉ ܮൌ ͺǤͳͳ െ ൬
ͲǤ͵  ܥோூி
Figure 5-2. Model fits of bacterial burden at 24h in static time kill studies for Lee
1599 (A) and RIF (B) to obtain the parameter estimates such as E0, Emax and EC50.
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Table 5-2.

Results of three dimensional surface response assay.
Model

Observed effect
Model predicted effect

VUP
value

Ratio
(VUPobs/VUPpred)

274.84
271.86

1.01
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Figure 5-5. In vitro PK/PD dynamic time kill study for Lee 1599, RIF and its
combination with different doses.
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48h for all the treatment groups were arbitrarily selected for quantitative comparison as
shown in Figure 5-6. At higher doses of 100mg/kg Lee 1599 and 10mg/kg RIF, there is
an average of 4 log CFU/mL reduction in bacterial counts when the agents are
administered in combination as compared to 2.44 log CFU/mL by Lee 1599 alone or 3
log CFU/mL by RIF alone. Similarly, an approximate 4 log CFU/mL bacterial killing
was observed when 10mg/kg Lee 1599 was co-administered with 10mg/kg RIF as
compared to 1.73 log CFU/mL killing with 10mg/kg Lee 1599 alone. The efficacy
observed with both dose group including the higher RIF dose (100mg/kg Lee 1599 +
10mg/kg RIF and 10mg/kg Lee 1599 + 10mg/kg RIF) were almost identical. This can be
possibly due to a ceiling effect in the killing pattern by Lee 1599 when given with high
doses of RIF.
At much lower doses, an average of 2.5 log CFU/mL bacterial reduction was
observed with 1mg/kg 1599 + 0.5mg/kg RIF. A dose of 1mg/kg Lee 1599 did not show
any evidence for sterilizing activity. However, the same dose when co-administered with
0.5mg/kg RIF could improve bacterial killing in contrast to individual Lee 1599 dose at
48h and 72h (p < 0.05). All three sets of combination doses showed an increased bacterial
killing when both the agents were administered in combination. This is an indication of
an additive effect of both the anti-bacterial agents in combination.
In vivo studies
The results of our pharmacodynamic interaction assays of the Lee 1599-RIF
combination were subsequently compared to in vivo efficacy results after 4 weeks of
treatment in an acute M. tb infection model in mice performed by our collaborators, Dr.
Anne Lenaerts and her group at Colorado State University. The studies were carried out
in two different groups: A high dose aerosol (HDA) and low dose aerosol (LDA)
infection with 200mg/kg QD Lee 1599 (subcutaneously) and 10mg/kg QD RIF (oral)
administered as shown in Figure 5-7. The HDA group was inoculated with 3.5 log CFU
per mouse and LDA group was inoculated with 2 log CFU per mouse. For the HDA
group, the observed bacterial reduction was 2.14, 1.08 and 2.97 log CFU with Lee 1599,
RIF and combination of both drugs, respectively. The expected combined effect of Lee
1599 and RIF assuming there is no interaction between the two drugs can be calculated as
3.22 log CFU. Similarly, for the LDA group, the observed effect with combination was
2.79 log CFU and theoretical summation was 2.84 log CFU. The close proximity of the
observed and the expected value for efficacy of the combination regimens suggests that
Lee 1599 and RIF have an additive effect when given in combination.
Discussion
Spectinamide Lee 1599 has excellent anti-TB activity both in vitro and in vivo
and has demonstrated potency against MDR- and XDR-TB strains obtained from several
clinical isolates. It is a well-known fact that TB therapeutic regimen require a
combination of multiple anti-TB drugs. It is evident that eventually every drug against
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Figure 5-6. The bacterial log reduction with different doses using an in vitro
PK/PD dynamic time kill experiment.
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Figure 5-7. In vivo efficacy trial data showing bacterial burden reduction (log
CFU/mL) in the lungs of M. tb infected mice, N=6 for Lee 1599 and Lee 1599+RIF,
N=5 for RIF.
Notes: Lee 1599 was administered subcutaneously at 200mg/kg and RIF was dosed
orally at 10mg/kg. The results are significant for all dose groups at p<0.05 by pairwise
multiple comparison procedures (Tukey test).
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TB will be co-administered with other anti-TB drugs [21]. In our ongoing research
studies, we hypothesized an increase in pharmacodynamic effect when spectinamide Lee
1599 is co-administered with another established anti-TB drug and that this increase in in
vivo effect can be predicted by adequate in vitro assays. The model drug selected for the
purpose of our study was RIF, a first-line antibiotic used for TB therapy. The change in
pharmacodynamic effect upon co-administration of two drugs is frequently determined
using techniques such as the checkerboard assay, the E-test and time-kill curves both in
vitro and in vivo [118, 119]. We applied two of these methods for primary screening: the
checkerboard assay and the three dimensional surface response assay. As shown by our
results, there is a clear disconnect between the outcomes of these two methods as shown
in Table 5-3. The checkerboard assay suggested a synergistic interaction between Lee
1599 and RIF. However, the three dimensional surface response assays indicated an
additive effect between the two compounds.
The primary reason for the difference between these two methods is likely rooted
in the underlying principles of both methods. The basis of null interaction for the FICI
score derived from the checkerboard assay is the Loewe additivity method. However,
there are several pitfalls associated with the checkerboard assay: (1) The initial bacterial
load for testing interactions is much lower (OD600 0.01 or 105 CFU/mL) than what is
observed in in vivo studies or in patients [120, 121]. (2) The endpoint is often based on
visual inspection and very subjective, increasing the possibility of erroneous results.
Since, it follows a 2-fold dilution technique; there is a high possibility of one-well errors.
Though this error may be undervalued assuming a miniscule marginal error, the error is
magnified and the extent of allowance increases at higher dilutions [122]. (3) Moreover,
there are various methods to calculate the FICI index using the checkerboard assay and
there has been variability reported with different methods of interpretation of
checkerboard synergy testing [123].
To overcome these limitations, we advanced with a quantitative, parametric three
dimensional surface response approach proposed by Tam et al. The surface response
approach has several advantages over the checkerboard assay: (1) The endpoint is the
quantification of bacterial counts on agar plates as opposed to visual inspection. (2) The
initial number of bacteria pre-dose, approximately 107-108 CFU/mL, is much higher
relative to the checkerboard assay and comparable to in vivo mouse infection models. (3)
The bacterial inoculum is in higher volumes of media providing a more conducive
environment with fresh nutrients for bacterial growth. (4) The difference in bacterial
counts in dosing and control groups after 24h of incubation normalizes the bacterial
reduction thus providing us with a measure for extent of bacterial killing. Based on these
facts, the indication of combination effects from the response surface assay seems to be
more reliable compared to the checkerboard assay based on the above mentioned
rationales.
It is obligatory to validate the results obtained from two different screening
assays, particularly if the two applied methodologies provide discordant results as in our
study. We therefore performed an in vitro PK/PD model based dynamic time-kill study as
opposed to static time kill studies to validate the preliminary findings and confirm the
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Table 5-3.
methods.

Summary of results of pharmacodynamics interactions from different
Method
Checkerboard assay
3D surface response assay
Dynamic time kill curves
In vivo mouse studies
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Indication
Synergy
Additive effect
Additive effect
Additive effect

authenticity of the above mentioned assays. The in vitro PK/PD model based time-kill
curves were performed under dynamic conditions and take into account the fluctuating
concentration of drug over time mimicking the pharmacokinetic conditions observed in
vivo. Although the hollow fiber infection model (HFIM) is now used by an increasing
number of research groups for this purpose, our previously used in vitro PK/PD model
has several advantages over the use of HFIM if used for the compound screening. Some
of the major limitations of the HFIM is non-specific drug binding (especially highly
lipophilic compounds) to the hollow fiber capillaries producing misleading results,
relatively high cost and complex operation. Our in vitro model uses a substantially easier
setup, and can be sterilized and reused between two cycles of different studies. This
makes the in vitro model very cost-effective and ideal for use in exploratory trials to test
multiple dose and dosing regimens [39].
The results from the time-kill curves experiments indicate a moderate increase in
bacterial reduction with combination treatment as compared to monotherapy. The net
bacterial reduction with combination is approximately the algebraic sum of bacterial
reduction caused by the two agents during monotherapy. Thus, the time-kill results
indicated an additive effect between Lee 1599 and RIF. To compare the efficacy among
the treatment regimens, we selected the 48h timepoint as the bacterial counts were below
the quantification limit at later timepoints in the Lee 1599 100mg/kg QD and RIF
10mg/kg QD dose groups. The bacterial killing increases with increasing doses of Lee
1599 or RIF alone, which is expected based on their previously observed non-linear dose
response relationships. The combined effect at low doses of Lee 1599 1mg/kg and RIF
0.5mg/kg was marginally higher than RIF 0.5mg/kg. However, when higher doses for
both Lee 1599 and RIF are co-administered there is a substantial increase in the reduction
of bacterial counts. Theoretically, the bacterial reduction for the Lee 1599 100mg/kg +
RIF 10mg/kg group should be higher than Lee 1599 10mg/kg + RIF 10mg/kg group. The
observed effect for both groups, Lee 1599 100mg/kg+RIF 10mg/kg and Lee 1599
10mg/kg + RIF 10mg/kg group, however, showed similar efficacy, that was significantly
higher than for the groups treated with Lee 1599 alone (p<0.05). This clearly suggests
that doses of 10mg/kg and 100mg/kg of Lee 1599 when given in combination with
10mg/kg RIF have the same efficacy possibly due to a ceiling effect.
There is always experimental variability associated with individual data points.
The method of using a specific time point to compare the efficacy of different dose group
as we applied can be erroneous, as it does not capture the cumulative effect of the
treatment. To overcome this limitation, we calculated the area-under the curve (AUC0-t)
for the individual time-kill curves to establish a cumulative measure of the overall effect.
As the time-kill experiments were terminated at different time points, we determined
AUC0-48 for all time-kill curves and normalized them with the control group. The
percentages of AUC0-48 ratios were calculated to compare different groups as shown in
Table 5-4. The higher the percentages, the higher the killing. The %ratios were larger for
combination therapy as compared to monotherapy. The %ratios for Lee 1599 100mg/kg +
RIF 10mg/kg was larger than Lee 1599 10mg/kg + RIF 10mg/kg indicating more
bacterial kill for the former group. Also, at lower doses (Figure 5-8), the %ratio for Lee
1599 1mg/kg + RIF 0.5mg/kg group was larger than the individual Lee 1599 and RIF
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Table 5-4.
Comparison of %AUC ratios (the %AUC were normalized with AUC
of control group).
Group
Lee 1599 100mg/kg + RIF 10mg/kg
Lee 1599 10mg/kg + RIF 10mg/kg
Lee 1599 100mg/kg
Lee 1599 10mg/kg
RIF 10mg/kg
Lee 1599 1mg/kg + RIF 0.5mg/kg
RIF 0.5mg/kg
Lee 1599 1mg/kg
Control
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%AUC ratio
94.1
91.7
93.9
86.1
84.5
85.9
74.9
68.8
0.0

Figure 5-8. Comparison of %AUC ratios after the %AUC were normalized with
AUC of control group indicating higher the %AUC ratio, greater the bacterial
killing.
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treatment arms. The enhanced killing in the combination group suggests an additive
effect of both the agents. Thus, the AUC0-t ratios may be a better estimate for comparison
of kill curves than a point estimate as it captures the dynamic range of the bacterial timekill effect.
The above in vitro results are corroborated by in vivo findings suggesting a
additive effect between Lee 1599 and RIF. The in vivo studies were performed using
different bacterial loads (HDA and LDA bacterial burden) for treatment. There is no
“gold standard” definition of synergy observed under in vitro or in vivo conditions. Of the
many definitions reported in the literature, synergy is commonly defined as ≥ 2 log
CFU/mL reduction by combination as compared to single therapy [124, 125]. Based on
this assessment, we interpreted the in vivo results to be an additive effect. However, these
definitions of synergy are not necessarily translatable to clinical scenarios where the
endpoint of treatment is an improvement in the patient’s condition. It is challenging to
identify an additive effect or synergistic effect under clinical conditions as one can
usually not quantify bacterial counts in patients. The primary application of these drug
interaction characteristics determined under preclinical conditions is to adjust the dose
and dosing regimen for the combination therapy and balancing the efficacy profile of the
drugs without imparting any toxicity to the patient. In view of these considerations,
drawing a line between additive effect and synergy at the preclinical stage may not give
any edge for dose optimization in the clinic. Hence, the purpose of the drug interaction
assays should focus on whether the combination is more efficacious or less toxic as
compared to single dose treatment.
Conclusions
In summary, it is crucial to carry out in vitro experiments on pharmacodynamic
interactions for antibiotics early during the preclinical drug development phase to test
potential interactions between two or more molecules. The results from the checkerboard
assay or any other qualitative analysis assay should be used with caution. It is advised to
confirm the results with quantitative methods such as three dimensional surface response
assay, dynamic time kill curve experiments or in vivo studies to get precise information
about the drug interaction in question. Our studies show that the preclinical drug
development process can be hindered or misguided if decisions are based on only one
qualitative assay. In addition, the purpose of the drug interaction assays should focus on
whether the combination is more efficacious or less toxic as compared to single dose
treatment rather than trying to decipher between additivity and synergism.
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CHAPTER 6.

SUMMARY

The number of resistant strains of M. tb that have increased at an alarming rate
has convinced researchers to focus on the discovery of new anti-tuberculosis drugs to
combat this pandemic. To contribute to solutions for this problem, our research group
discovered a novel series of anti-tuberculosis agents called spectinamides, semi-synthetic
analogs of spectinomycin. Spectinamides are potent inhibitors of mycobacterial
ribosomes and overcomes efflux mediated drug resistance in M. tb. Multiple of the
compounds in the spectinamide series have shown an excellent in vitro activity and
acceptable drug-like properties, thus making them excellent preclinical drug candidates.
We hypothesized that a pharmacometrics-directed quantitative approach for integrated
PK/PD characterization can guide the selection of lead candidate compounds and is more
predictive of in vivo efficacy than some qualitative of semi-quantitative standard
approaches.
The screening for potential lead drug candidates included multiple experiments to
determine the pharmacokinetic parameters. In vitro screening demonstrated that
spectinamides have low plasma protein binding and are stable against hepatic microsomal
activity. The pharmacokinetics studies in rats revealed that renal excretion is the major
route of elimination for most spectinamides. This route of elimination suggests that there
is a low potential for drug-drug interactions during combination pharmacotherapy as seen
with agents that undergo extensive hepatic metabolism. Because spectinamides are highly
hydrophilic, distribute well in aqueous distribution spaces, and show low plasma protein
binding, they are advantageous as therapeutic candidates over other new anti-TB agents
where most tend to be lipophilic and have high plasma protein binding. This results in
spectinamides being able to target bacterial subpopulations that are unreachable by more
lipophilic compounds.
An important aspect in the safety of novel drug candidates is their biodistribution
and potential accumulation in tissues. On the other hand, intracellular uptake into
macrophages is a prerequisite for antibiotic activity against M. tb residing inside infected
macrophages. Our quantitative macrophage uptake studies showed that Lee 1329,
Lee1445 and Lee 1599 had significantly higher macrophage uptake than spectinomycin
and streptomycin.
The biodistribution of spectinamides was determined using a tritium labelled Lee
1329. About 70% of administered radioactivity was recovered in urine and 12.6% in
feces, with a total mass balance of 84.7%. Total radioactivity showed similar activitytime profiles for the first 2h after I.V. administration. Deviation at later time points
suggests formation of circulating metabolites with longer half-life than the parent drug.
Cmax after the 1st dose and the 8th dose is similar: 3.39μCi/mL and 3.55μCi/mL,
suggesting no relevant accumulation of parent drug and metabolites. The activity of
radiolabel was 3 times higher in lungs and spleen as compared to whole blood,
suggesting good tissue penetration of Lee 1329. The results support the earlier findings
that the major elimination pathway for Lee 1329 is renal excretion and that the compound
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accumulates neither in blood nor in tissues during multiple dosing with a BID regimen in
rats, which is an important aspect in the safety profile of spectinamides.
The minimum inhibitory concentration (MIC) is one of the key pharmacodynamic
parameters used to compare and differentiate drug candidates. However, point estimates
of pharmacodynamic activity such as MIC do not take into account the dynamic
interaction between bacteria and fluctuating exposure to unbound drug during dosing in
vivo. We thus applied an in vitro PK/PD model system to establish the quantitative
interaction between bacterial growth and time-varying drug concentration for the
emerging lead Lee 1599. The obtained results were used to identify the optimal PK/PD
index driving Lee 1599’s efficacy, and to perform model-based numerical simulations to
determine appropriate dosing regimens for further in vivo efficacy trials. The results
indicate that Lee 1599 exhibits a dose-dependent bactericidal effect. Lee 1599 showed up
to 4-log reductions in bacterial counts at 100mg QD dosing. The PK/PD indices
demonstrate that Lee 1599 elicits a concentration- and time-dependent killing with
AUC/MIC as the optimal index. The in vitro PK/PD simulated profile suggests that
higher doses with shorter dosing intervals may demonstrate optimal efficacy in vivo.
With an increasing frequency of mycobacterial resistant strains, there is an
emerging need for robust and effective combination therapy. The conventional screening
method for determining pharmacodynamic drug interactions using the Checkerboard
assay depends on a subjective endpoint of growth inhibition and fails to provide any
information on extent of bacterial growth or kill over time. We applied parametric
approach to quantitatively assess the pharmacodynamics drug interaction between the
lead candidate compound Lee 1599 and rifampicin. The three dimensional surface
response assay demonstrated that there is an additive effect between both agents as
opposed to the checkerboard assay, which showed synergism between these agents. The
results of the surface response assay were validated using an in vitro PK/PD model for
combination agents and in vivo efficacy trials. These results suggest that the quantitative
response surface assay may be a screening tool for drug interactions that is more
predictable of in vivo interactions than the traditional checkerboard assay. In addition, the
additive effect between Lee 1599 and rifampicin suggest that a combination therapy may
warrant optimal efficacy results at lower doses than single drug therapy of either drug.
In conclusion, we have successfully supported the further development of
spectinamides using a pharmacometric approach. We have contributed to the selection of
lead candidate compounds such as Lee 1599 using quantitative PK/PD approaches in its
pre-clinical development. The application of PK/PD knowledge is essential for
translating the in vitro screening assay findings to the in vivo stage. The results of the
above studies may serve to illustrate the optimization of anti-infective agents in the early
drug discovery and development.
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